

Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications

Bryce J. B. Nelson¹, Jan D. Andersson^{1,2} and Frank Wuest^{1,*}

- ¹ Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada; bjnelson@ualberta.ca (B.J.B.N.); janderss@ualberta.ca (J.D.A.)
- ² Edmonton Radiopharmaceutical Center, Alberta Health Services, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada
- * Correspondence: wuest@ualberta.ca; Tel.: +1-780-391-7666; Fax: +1-780-432-8483

Abstract: This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α -particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α -emitters, including ²²⁵Ac, ²¹³Bi, ²²⁴Ra, ²¹²Pb, ²²⁷Th, ²²³Ra, ²¹¹At, and ¹⁴⁹Tb; the production techniques and proper handling of α -emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.

Keywords: targeted alpha therapy; alpha particle therapy; targeted radionuclide therapy; theranostics; actinium-225; bismuth-213; astatine-211; radium-223; thorium-227; terbium-149



Citation: Nelson, B.J.B.; Andersson, J.D.; Wuest, F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. *Pharmaceutics* **2021**, *13*, 49. https://doi.org/10.3390/ pharmaceutics13010049

Received: 2 December 2020 Accepted: 23 December 2020 Published: 31 December 2020

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Radionuclide therapy has been employed frequently in the past several decades for disease control, curative therapy, and pain management applications [1]. Targeted radionuclide therapy (TRT) is advantageous as it delivers a highly concentrated dose to a tumor site—either directly to the tumor cells or to its microenvironment—while sparing the healthy surrounding tissues. It has been clinically demonstrated using a variety of radionuclides to treat malignancies, including polycythemia, cystic craniopharyngioma, hyperthyroidism, synovitis and arthritis, and numerous cancers, such as thyroid cancer, bone tumors and metastasis, hepatic metastasis, ovarian cancer, neuroendocrine tumors, leukemia, lymphoma, and metastatic prostate cancer [2–4]. Since radionuclide therapy targets diseases at the cellular level, it has advantages for treating systemic malignancies such as tumor metastases over other forms of therapy such as external beam therapy, where full body irradiation is impossible. In addition to being minimally invasive, radionuclide therapy can be shorter in duration than chemotherapy [2].

In TRT, therapeutic radionuclides including alpha (α), beta (β^-), and Auger electron emitters are typically conjugated to a targeting vector such as monoclonal antibodies, biomolecules, peptides, nanocarriers, and small-molecule inhibitors. To maximize the therapeutic efficacy of a TRT radiopharmaceutical, its radionuclide decay pathway, particle emission range, and relative biological effectiveness should be matched appropriately for a given tumor mass, size, radiosensitivity, and heterogeneity [1].

This review focuses on targeted alpha therapy (TAT), outlined by the graphical abstract in Figure 1. A detailed overview of α -emitting radionuclides currently employed in radiotherapy is presented and compared to radionuclides with different emissions, including β^- particle and auger electron emitters. Production techniques for α -emitters are outlined, including their separation and unique handling requirements, followed by their radiochemistry and targeting characteristics. Preclinical developments and clinical



applications of α -emitters are discussed along with current limitations, potential areas for improvement, and anticipated applications.

(a) Radionuclide Production and Automated Processing (b) Radiolabeling

(c) Targeted Alpha Radiotherapy

Figure 1. Key aspects of targeted alpha therapy: (**a**) radionuclide production via cyclotron, nuclear reactor or generator decay, and shielded automated processing; (**b**) radiolabeling the alpha-emitting radionuclide to a suitable targeting vector to form a bioconjugate; and (**c**) targeted alpha radiotherapy precisely destroys tumor cells while sparing surrounding healthy tissue.

2. Selecting Radionuclides for Radiotherapy

When selecting a radionuclide for clinical application, the physical and biochemical characteristics must be considered. Physical characteristics include physical half-life, type of emissions, energy of the emissions, daughter products, method of production, and radionuclidic purity. Biochemical characteristics include tissue targeting, retention of radioactivity in the tumor, in vivo stability, and toxicity [2]. For radiotherapy, it is desirable to have a high linear energy transfer (LET), where there is a high ionization energy deposited per unit length of travel. Radionuclides with a high LET deposit radioactive emission energy within a small range of tissue, thereby sparing surrounding healthy tissue and keeping the radioactive dose within, as much as possible, the patient's organ to be treated. It can also be advantageous for the therapeutic radionuclide, or a complementary theranostic radionuclide, to emit positrons (β^+) or gamma (γ) radiation. This enables positron emission tomography (PET) or single photon emission tomography (SPECT) imaging and visualization of radiopharmaceutical distribution within a patient's body, permitting treatment monitoring. Table 1 outlines key characteristics of α , β^- , and auger electron emitters, and some clinical applications for cancer TRT that have been explored.

Radioactive Particle	Decay Characteristics	Clinical Cancer Applications	Reference
Beta particle(β^-)	Emission energy per decay: 50–2300 keV Range: 0.05–12 mm Linear Energy Transfer (LET): 0.2 keV/µm	Metastatic castration resistant prostate cancer, acute myeloid leukemia, neuroendocrine tumors, acute lymphocytic leukemia, ovarian carcinomas, gliomas, metastatic melanoma, colon cancer, bone metastases	[1,3,4]
Auger electron (AE)	Emission energy per decay: 0.2–200 keV Range: 2–500 nm LET: 4–26 keV/µm	Advanced pancreatic cancer with resistant neoplastic meningitis, advanced sst-2 positive neuroendocrine and liver malignancies, metastatic epidermal growth factor receptor (EGFR)-positive breast cancer, glioblastoma multiforme	[1,5]
Alpha particle (α)	Emission energy per decay: 5–9 MeV Range: 40–100 μm LET: 80 keV/μm	Metastatic castration resistant prostate cancer, relapsed or refractory CD-22-positive non-Hodgkin lymphoma, acute myeloid leukemia, neuroendocrine tumors, ovarian carcinoma, gliomas, intralesional and systemic melanoma, colon cancer, bone metastases	[1,3,4]

Table 1. Key characteristics of α , β^- , and auger electron emitters and their clinical applications.

 β^- emitting radioisotopes have a relatively long pathlength ($\leq 12 \text{ mm}$) and a lower LET of ~0.2 keV/µm, giving them effectiveness in medium–large tumors [1]. However, they lack success in solid cancers with microscopic tumor burden. This may be attributed to their emissions releasing the majority of their energy along a several millimeter long electron track, irradiating the surrounding healthy tissue instead of depositing their main energy into the micro-metastatic tumor cells where the radionuclide was delivered [6].

Clinical success has been demonstrated with the β^- emitters ⁹⁰Y and ¹³¹I conjugated with anti-CD20 monoclonal antibodies in follicular B-cell non-Hodgkin lymphoma [6], ¹⁷⁷Lu-labeled prostate-specific membrane antigen (PSMA) peptides in metastatic, castration-resistant prostate cancer (CRPC) and ¹⁷⁷Lu-DOTATATE for neuroendocrine tumors [7,8].

Auger electrons have a medium LET (4–26 keV/ μ m) [1]; however, their short pathlength of 2–500 nm limits the majority of their effects to within single cells, requiring the radionuclide to be transported into the cell and preferably incorporated into DNA to achieve high lethality. They can also kill cancer cells by damaging the cell membrane and kill non-directly targeted cells through a cross-dose or bystander effect [9]. Clinical studies with Auger electrons for cancer therapy have been limited; however, some encouraging results were obtained using [¹¹¹In]In-DTPA-octreotide in rats with pancreatic tumors, [¹²⁵I]I-IUdR where tumor remissions were achieved, and [¹²⁵I]I-mAb 425 where the survival of glioblastoma patients improved [5,10,11]. However, it has also been determined that some Auger electron emitting compounds, such as [¹²³I]I-IUdR and [¹²⁵I]I-IUdR only kill cells in the S-phase of the cell cycle, highlighting a potential treatment limitation [12].

 α -particles have a high LET (80 keV/µm) and a moderate pathlength (50–100 µm), giving them an effective range of less than 10 cell diameters. This makes them suitable for microscopic tumor cell clusters, while sparing normal organs and surrounding healthy tissues. Importantly, α -particle lethality is not dependent on the cell cycle or oxygenation, and the DNA damage is often via double strand and DNA cluster breaks and is therefore much more difficult to repair than β^- damage [6]. It has been estimated that to attain a single cell kill probability of 99.99%, tens of thousands of β^- decays are required, whereas only a few α -decays at the cell membrane achieves the same kill probability [13]. From this, it has been estimated that one α particle transversal can kill a cell [14]. Most α -emitters are conjugated to a wide range of targeting vectors for delivery to their target site, though some have intrinsic targeting properties, such as the affinity of ²²³Ra-dichloride for bone [1]. Preclinical and clinical studies using α -emitters have been ongoing for a variety of cancers, some of which include recurrent brain tumors, recurrent ovarian cancers, human

epidermal growth factor receptor-2 (HER-2) positive cancers, myelogenous leukemia, non-Hodgkin lymphoma, metastatic melanoma, and skeletal metastases in prostate cancer [6]. Of these, the most theranostic research is performed on prostate and neuroendocrine tumors (NETs). Examples of studies are numerous—one preclinical study using [²¹²Pb]Pb-trastuzumab found a single injection reduced tumor growth by 60–80%, reduced aortic lymph node metastasis, and prolonged survival or tumor-bearing mice [15]. Another study outlined how α-particle radiotherapy for metastatic castration resistant prostate cancer using [²²⁵Ac]Ac-PSMA-617 was able to overcome resistance to [¹⁷⁷Lu]Lu-PSMA-617 β⁻-particle therapy [16]. Additionally, a study using [²¹³Bi]Bi-DTPA and [²¹³Bi]Bi-DOTATATE in mice resulted in a factor of six increase in cell killing compared to [¹⁷⁷Lu]Lu-DOTATATE [17,18]. These studies highlight the clinical importance and potential of α-emitters, and their potential to be more efficient and effective than β⁻- therapy.

3. Alpha Emitter Decay Properties

As emissions from radioactive decay, α -particles are naked ⁴He nuclei with a +2 charge. They are 7300 times larger than the mass of β^- and Auger electrons, giving them significant emission momentum that reduces deflection and results in a near-linear emission path, as opposed to the winding path of β^- particles. With an emission kinetic energy between 5–9 MeV, coupled with a particle range of 50–100 μ m, this classifies α -particles as high LET. The energy distribution between the alpha particle and the recoiling daughter atom is typically 98% to 2%. Upon decay, energy imparted to the daughter recoil atom can reach 100 keV [19], which is far higher than the binding energy of the strongest chemical bonds, resulting in release of the daughter isotope from its targeting vector. An example is ²¹⁹Rn, which has a daughter recoil range of 88 nm in a cellular environment [19]. These daughters often have a serial decay chain with their own α -emitting progeny, leading to untargeted irradiation of surrounding tissues. As a result, only a limited number of α -emitting radioisotopes are suitable for therapy due to their decay characteristics. The half-life of the radionuclide should be reasonable for therapy; it should not be too short to allow sufficient time for production, radiopharmaceutical synthesis, and delivery to the patient, and it, as well as the half-life of any daughter radionuclide, should not be too long to avoid excess patient dose.

The recoil energy caused by the decay of α -emitters invariably destroys α -emittertargeting vector chemical bonds, often releasing α -emitting progeny with different chemistries that can lead to undesirable toxicities. The presence of γ -ray emissions in an α -emitter decay chain is also of interest for imaging purposes. Therefore, it is important to understand the half-lives, emissions, and decay characteristics when selecting clinically relevant α emitters. Figure 2 depicts decay chains that contain some common therapeutic α -emitters, and Table 2 outlines the decay characteristics of some notable α -emitters used in α therapy, including their daughters, half-lives, decay energies, and emissions.




Figure 2. Decay chains of some common therapeutic α -emitters. Reproduced from [6], Frontiers, 2014.

Descrit	Daushtar	TT 16 T .C	Emission Type (Energy, Intensity)				
Parent	Daughters	Halt-Lite	α	β^-	β+	γ	X-ray
²²⁵ Ac		9.9 d	5.8 MeV, 50.7%			100 keV, 1%	18.6 keV, 13%
	²²¹ Fr	4.8 min	6.3 MeV, 83.3%			218 keV, 11.4%	17.5 keV, 2%
	²¹⁷ At	32.3 ms	7.1 MeV, 99.9%				
	²¹³ Bi	45.6 min	5.9 MeV, 1.9%	492 keV, 66%		440 keV, 26%	79 keV, 1.8%
	²¹³ Po	3.72 μs	8.4 MeV, 100%				
	²⁰⁹ Tl	2.16 min	,	178 keV, 0.4%		1567 keV, 99.7%	75 keV, 9.7%
	²⁰⁹ Pb	3.23 h		198 keV, 100%			
	²⁰⁹ Bi	Stable					
²²⁴ Ra		3.63 d	5.7 MeV, 95%			241 keV, 4.1%	
	²²⁰ Rn	55.6 s	6.3 MeV, 99.9%				
	²¹⁶ Po	0.15 s	6.8 MeV, 99.9%				
	²¹² Pb	10.6 h		93.5 keV, 83%		238 keV, 43.6%	77 keV, 17.5%
	²¹² Bi	60.6 min	6.1 MeV, 25%	834 keV, 55%		727 keV, 6.7%	15 keV, 7%
	²¹² Po	0.30 μs	8.8 MeV, 100%				
	²⁰⁸ Tl	3.1 min		650 keV, 49%		2614 keV, 99.9%	
	²⁰⁸ Pb	Stable					
²²⁷ Th		18.7 d	6.0 MeV, 100%			236 keV, 13%	19 keV, 37%
	²²³ Ra	11.4 d	5.7 MeV, 100%			269 keV, 14%	83 keV, 25%
	²¹⁹ Rn	3.96 s	6.8 MeV, 79.4%			271 keV, 10%	16 keV, 1%
	²¹⁵ Po	1.78 ms	7.4 MeV, 99.9%				
	²¹¹ Pb	36.1 min		471 keV, 91%		404 keV, 3.8%	
	²¹¹ Bi	2.14 min	6.6 MeV, 83.5%	172 keV, 0.3%		351 keV, 13%	
	²⁰⁷ Tl	4.77 min		492 keV, 99.7%			
	²⁰⁷ Pb	Stable					
²¹¹ At		7.2 h	5.9 MeV, 42%				79 keV, 21%
	²¹¹ Po	0.52 s	7.5 MeV, 98.9%				
	²⁰⁷ Bi	31.6 y				570 keV, 97.8%	
	²⁰⁷ Pb	Stable					
¹⁴⁹ Tb		4.1 h	4.0 MeV, 16.7%		638 keV, 3.8%	352 keV, 29.4%	43 keV, 36%
	¹⁴⁹ Gd	9.3 d				150 keV, 48%	42 keV, 55%
	¹⁴⁹ Eu	93.1 d					40 keV, 40%
	¹⁴⁹ Sm	Stable					
	¹⁴⁵ Eu	5.9 d			740 keV, 1.5%	894 keV, 66%	40 keV, 40%
	¹⁴⁵ Sm	340.3 d				61 keV, 12%	39 keV, 71%
	¹⁴⁵ Pm	17.7 y				72 keV, 2%	37 keV, 40%
	¹⁴⁵ Nd	Stable					

Table 2. Notable α -emitters and the	eir daughters, half-lives, deca	ay energies, and emission	types [20].

 225 Ac (t_{1/2} = 9.9 d, 5.8 MeV α particle) decays to 209 Bi with six intermediate radionuclide progenies. These daughters include 221 Fr (t_{1/2} = 4.8 min; 6.3 MeV α particle and 218 keV γ emission), 217 At (t_{1/2} = 32.3 ms; 7.1 MeV α particle), 213 Bi (t_{1/2} = 45.6 min; 5.9 MeV α particle, 492 keV β^- particle and 440 keV γ emission), 213 Po (t_{1/2} = 3.72 µs; 8.4 MeV α particle), 209 Tl (t_{1/2} = 2.2 min; 178 keV β^- particle), 209 Pb (t_{1/2} = 3.23 h; 198 keV β^- particle) and 209 Bi (stable). From this, a single 225 Ac decay yields a total of four α , three β^- disintegrations, and two γ emissions, which classifies 225 Ac as a "nanogenerator" or "in vivo generator". Therefore, the 9.9 d half-life of 225 Ac, the multiple α particle emissions in its decay chain, and its rapid decay to 209 Bi make 225 Ac an attractive candidate for TAT [21]. The γ emissions would be useful for SPECT imaging of in vivo radiopharmaceutical distribution, giving the 225 Ac decay series theranostic potential; however, due to

the potency of ²²⁵Ac, the small administered doses and correspondingly low γ emissions would make planar SPECT imaging difficult [21]. Of note, the intermediate ²¹³Bi possesses attractive potential and can be separated from the ²²⁵Ac decay series for use. However, the short 45.6 min half-life of ²¹³Bi presents challenges for processing, radiolabeling, and radiopharmaceutical administration, resulting in a limited time in circulation to accumulate at its target site and achieve its intended therapeutic effects.

²²⁴Ra (t_{1/2} = 3.63 d, 5.7 MeV α particle, 241 keV γ emission) decays to ²⁰⁸Pb with six intermediate radionuclide progenies. These daughters include ²²⁰Rn (t_{1/2} = 55.6 s, 6.3 MeV α particle), ²¹⁶Po (t_{1/2} = 0.15 s, 6.8 MeV α particle), ²¹²Pb (t_{1/2} = 10.6 h, 93.5 keV β⁻ particle, 238 keV γ emission), ²¹²Bi (t_{1/2} = 60.6 min, 6.1 MeV α particle, 834 keV β⁻ particle, 727 keV γ emission), ²¹²Po (t_{1/2} = 0.30 µs, 8.8 MeV α particle), ²⁰⁸Tl (t_{1/2} = 3.1 min, 650 keV β⁻ particle, 2614 keV γ emission), and ²⁰⁸Pb (stable). From this, a single ²²⁴Ra decay yields a total of four α particles, two β⁻ disintegrations, and six γ emissions, also classifying ²²⁴Ra as a "nanogenerator". The bone-seeking properties of ²²⁴Ra and its favorable half-life has resulted in its use in α-therapy, and its intermediates ²¹²Pb and ²¹²Bi show potential for TAT, with ²¹²Pb preferable to ²¹²Bi for administration due to the longer half-life of ²¹²Pb, permitting more dose from its ²¹²Bi progeny to be delivered [1].

²²⁷Th (t_{1/2} = 18.7 d, 6.0 MeV α particle, 236 keV γ emission) decays to ²⁰⁷Pb with six intermediate radionuclide progenies. These daughters include ²²³Ra (t_{1/2} = 11.4 d, 5.7 MeV α particle, and 269 keV γ emission), ²¹⁹Rn (t_{1/2} = 3.96 s, 6.8 MeV α particle, 271 keV γ emission), ²¹⁵Po (t_{1/2} = 1.78 ms, 7.4 MeV α particle), ²¹¹Pb (t_{1/2} = 36.1 min, 471 keV β⁻ particle, 404 keV γ emission), ²¹¹Bi (t_{1/2} = 2.14 min, 6.6 MeV α particle, 172 keV β⁻ particle, 351 keV γ emission), ²⁰⁷Tl (t_{1/2} = 4.77 min, 492 keV β⁻ particle), and ²⁰⁷Pb (stable). ²²⁷Th and ²²³Ra are both nanogenerators, releasing up to four α particles during the decay chain, and their γ emissions allow for imaging [1].

²¹¹At (t_{1/2} = 7.2 h, 5.9 MeV α particle) decays to ²⁰⁷Pb with two intermediate radionuclide progenies in separate paths. These daughters include ²⁰⁷Bi (t_{1/2} = 31.6 y, electron capture) which decays to ²⁰⁷Pb and ²¹¹Po (t_{1/2} = 0.52 s, 7.5 MeV α particle, Kα x-rays) which decays to ²⁰⁷Pb. The decay to ²¹¹Po would permit in vivo imaging of ²¹¹At using the emitted Kα x-rays.

¹⁴⁹Tb ($t_{1/2}$ = 4.1 h, 4.0 MeV α particle, 638 keV β⁺ particle), decays to ¹⁴⁹Sm and ¹⁴⁵Nd in two separate paths. In one path, its daughters include ¹⁴⁹G ($t_{1/2}$ = 9.28 d), ¹⁴⁹Eu ($t_{1/2}$ = 93.1 d, electron capture), and ¹⁴⁹Sm (stable). The other path includes ¹⁴⁵Eu ($t_{1/2}$ = 5.9 d, 740 keV β⁺ particle, 894 keV γ emission), ¹⁴⁵Sm ($t_{1/2}$ = 340.3 d, electron capture, 61 keV γ emission), ¹⁴⁵Pm ($t_{1/2}$ = 17.7 y, electron capture, 72 keV γ emission), and ¹⁴⁵Nd (stable) [22]. The decay scheme for ¹⁴⁹Tb is quite favorable since it releases short-range α particles from only one radionuclide, with complementary γ emissions and positrons that can be employed for imaging purposes in an "alpha-PET" combination [23,24]. Having only one α-emitter in its decay scheme implies a minimal toxicity from daughter recoil during radioactive decay, which should reduce excessive dose burden [25].

4. Alpha Emitter Production, Separation, and Handling

Common production methods for clinically relevant α -emitters can involve a cyclotron that accelerates and bombards a target using variety of particles, including protons, alpha particles, lithium and carbon ions, and nuclear reactors such as fast breeder reactors [26]. α -emitters are often delivered by a generator, where a parent isotope decays to the desired radionuclide that is then extracted. Current, anticipated, and potential production methods for various α -emitters are outlined in Table 3.

α Emitter	Production Method	Status	Reference
²²⁵ Ac	²²⁹ Th/ ²²⁵ Ac generator	Production	[26]
	226 Ra(p,2n) 225 Ac	Research	[26]
	226 Ra $(\gamma, n)^{225}$ Ra	Potential	[26]
	²²⁶ Ra(n,2n) ²²⁵ Ra	Potential	[26]
	²²⁶ Ra(d,3n) ²²⁵ Ac	Potential	[26]
	²³² Th(p,x) ²²⁵ Ac	Research	[26]
²¹³ Bi	²²⁵ Ac generator	Production	[17]
²²⁴ Ra	²²⁸ Th/ ²²⁴ Ra generator	Previously used	[27]
²¹² Bi	²²⁴ Ra/ ²¹² Bi generator	Production	[28]
²¹² Pb	²²⁴ Ra/ ²¹² Pb generator	Production	[28]
²²⁷ Th	²²⁷ Ac decay	Production	[28]
	²³⁵ U decay	Production	[28]
²²³ Ra	²²⁷ Th/ ²²³ Ra generator	Production	[28]
²¹¹ At	209 Bi(α ,2n) 211 At	Production	[29]
	²³² Th(p,x) ²¹¹ Rn	Research	[28]
	238 U(p,x) ²¹¹ Rn	Research	[28]
	²⁰⁹ Bi(⁷ Li,5n) ²¹¹ Rn	Research	[30]
	²⁰⁹ Bi(⁶ Li,4n) ²¹¹ Rn	Research	[28]
¹⁴⁹ Tb	¹⁵² Gd(p,4n) ¹⁴⁹ Tb	Research	[25]
	$^{nat}Nd(^{12}C_{r}xn)^{149}Dy \rightarrow ^{149}Tb$	Research	[31]
	¹⁵¹ Eu(³ He,5n) ¹⁴⁹ Tb	Research	[25]
	^{nat} Ta(p,x) ¹⁴⁹ Tb	Research	[25]
	$^{141}\Pr(^{12}C,4n)^{149}$ Tb	Research	[31]

Table 3. Current and anticipated production methods for therapeutic alpha emitter systems.

4.1. ²²⁵Ac and ²¹³Bi

²²⁵Ac and ²¹³Bi are currently produced from ²²⁹Th generators ($t_{1/2}$ = 7397 y). ²²⁹Th is sourced from the decay of fissile ²³³U, which was originally produced by neutron irradiation of natural ²³²Th. These generators can be milked over a 3-week period, permitting the separation of ²²⁵Ra and ²²⁵Ac. Current sources of ²²⁹Th that allow production of clinically sufficient activities of ²²⁵Ac/²²⁵Bi are available at the Directorate for Nuclear Safety and Security of the Joint Research Centre (JRC) of the European Commission in Karlsruhe, Germany, Oak Ridge National Laboratory (ORNL), the Institute of Physics and Power Engineering (IPPE), and recently Canadian Nuclear Laboratories. Since the 1990s, JRC has produced approximately 13 GBq annually, while ORNL has produced approximately 22 GBq/year, with these ²²⁵Ac products found safe for human administration and applied for patient treatment [32]. As of 2018, worldwide production of ²²⁵Ac has been 68 GBq/year, and while this does support preclinical studies, it only supports several hundred patients per year (when labeled with a 4-50 MBq dose) and prevents large scale 225 Ac/ 213 Bi generator production. However, no production technique has emerged as an effective and economic solution, leaving ²²⁵Ac supply as a patchwork of production methods with varying yields and radioisotopic purities [33]. It is clear that alternative methods of ²²⁵Ac production would enhance the supply chain and enable more widespread use.

Alternative production methods of ²²⁵Ac include neutron, proton, and deuteron irradiation of ²²⁶Ra targets, and high-energy proton irradiation of ²³²Th targets. Large-scale production of ²²⁵Ac by cyclotron proton irradiation of ²²⁶Ra via the ²²⁶Ra(p,2n)²²⁵Ac reaction shows promise. There is a significant 710 mb cross-section peak at 16.8 MeV proton energy, making this ideal for high-yield and cost-effective production for cyclotrons with beam energies less than 20 MeV [26]. Additionally, no long-lived actinium byproducts (²²⁷Ac, t_{1/2} = 21.8 y) are produced, and coproduced ²²⁶Ac (t_{1/2} = 29 h) via the ²²⁶Ra(p,n)²²⁶Ac and ²²⁴Ac (t_{1/2} = 2.8 h) via the ²²⁶Ra(p,3n)²²⁴Ac can be minimized by optimizing proton beam energy, and allowing for a "cool-down" period for decay post-irradiation due to their shorter half-lives compared to ²²⁵Ac. Although handling ²²⁶Ra is technically demanding due to its inherent radioactivity and 1600-year half-life, this method is preferred for largescale, cost-effective production [32]. Irradiating ²³²Th with high-energy protons has been demonstrated to produce several GBq of ²²⁵Ac using an intense proton beam irradiation for 10 days. However, this method produces a variety of radionuclidic impurities that must be removed by chemical separation and significant amounts of long-lived ²²⁷Ac (0.1–0.2% at end of bombardment) [32].

²¹³Bi generators have been developed by JRC and demonstrated to reliably prepare up to 2.3 GBq of ²¹³Bi radiolabeled compounds for therapeutic doses when loaded with up to 4 GBq of ²²⁵Ac [32]. They feature homogenous distribution of the ²²⁵Ac over the generator resin, minimizing radiolytic degradation and permitting operation for several weeks.

However, the availability of ²¹³Bi generators depends on the availability ²²⁵Ac generators, which are already in short supply [17].

4.2. ²²⁴Ra, ²¹²Bi, and ²¹²Pb

²²⁴Ra, ²¹²Pb, and ²¹²Bi can be produced from ²²⁸Th ($t_{1/2} = 1.92$ years) generators; however, radiolytic damage occurred to the Na₂TiO₃ resin, resulting in diminished yield and posing a radiation safety issue [27]. This resulted in a switch to ²²⁴Ra ($t_{1/2} = 3.6$ d)based generators from which ²¹²Bi and ²¹²Pb are obtained by elution. Despite producing high yields of ²¹²Pb (>90% of expected activity per daily elution) and its daughter ²¹²Bi, the generator must be replaced after 1–2 weeks due to the short half-life of ²²⁴Ra [34].

4.3. ²²⁷*Th and* ²²³*Ra*

²²⁷Th and ²²³Ra are available by separation from their parent ²²⁷Ac radionuclide. Production of ²²³Ra for clinical applications utilizes ²²⁷Ac/²²⁷Th generators, where the parent isotopes are on actinide chromatographic resins, and ²²³Ra-chloride solution is obtained after elution and purification on a cation exchange column [35].

4.4. ²¹¹At

²¹¹At can be produced using an α-particle beam to bombard natural bismuth at 28–29.5 MeV via the ²⁰⁹Bi(α,2n)²¹¹At reaction [29]. Despite being a straightforward method of production, the number of accelerators capable of a 28 MeV α beam limits the availability of ²¹¹At. ²¹¹At can also be produced via the ²⁰⁹Bi(⁷Li,5n)²¹¹Rn reaction, where ²¹¹Rn (t_{1/2} = 14 h) decays to ²¹¹At. This method, currently under development, exploits the longer half-life of ²¹¹Rn to extend the timeframe for effective distribution and use of ²¹¹At [30].

4.5. ¹⁴⁹Tb

The availability of ¹⁴⁹Tb is currently quite limited primarily due to inaccessible production routes. ¹⁴⁹Tb has been produced for use in preclinical α -therapy studies by the isotope and separation online facility (ISOLDE) at CERN, using high-energy proton irradiation of tantalum targets (1.4 GeV) and separation using a magnetic field. Potential production routes also include irradiation of rare ¹⁵²Gd targets with high-energy protons (>50 MeV), or spallation reactions using light ions at >500 MeV; however, these methods of production would require mass separation to avoid radioisotopic impurities [36]. ¹⁴⁹Tb was also produced using the ^{nat}Nd(¹²C,xn)¹⁴⁹Dy -> ¹⁴⁹Tb method by irradiating a thick target of ^{nat}Nd₂O₃ with ¹²C ions at 108 MeV. However, the scarcity of ¹²C accelerators limits this production avenue. Another method of production includes the ¹⁵¹Eu(³He,5n)¹⁴⁹Tb reaction, where ¹⁵¹Eu is bombarded by ³He particles from 40–70 MeV. This method results in high yield production of ¹⁴⁹Tb (3 GBq for an 8 h irradiation), and is advantageous due to target material availability and relatively simple radiochemical processing. The main drawback is the limited availability of high intensity ³He beams [25].

4.6. Alpha Emitter Handling

Once produced, α -emitters require special handling and equipment beyond the current capabilities of many radiopharmaceutical centers. Since the external protective layer

of skin stops α -particles, pure α -emitters are not an external radiation hazard. However, ingesting and internalizing α -emitters can cause serious effects, including cancer, genetic diseases, teratogenesis, and degenerative changes. To handle α -emitters, specialized equipment to detect α -particles should be employed, such as ZnS(Ag) scintillators to complement Geiger–Muller counters [37]. Detecting α -particles is difficult and time consuming due to the short range of α -particles in air, making a method of long-range detection of α -particles highly desirable [38]. This can be achieved by observing the secondary effects of α -emitters, such as the air-radioluminescence caused by ionization, where α -decay yields up to 400 UV photons in air. These photons have a much longer range in air than α -particles, and in areas with low background UV, they can be used to detect α -particles. One such detector under development has the capability to detect α -particles from a distance of about 40 cm [39]. Due to their properties, handling α -emitters requires much lower contamination removal levels than β^- -emitting radionuclides [1].

For α -emitters with low energy γ emissions, a well-ventilated fume hood with a glove box is sufficient. For α -emitters with high-energy γ emissions, work should be performed behind 15 cm lead bricks or inside a shielded hot cell with remote manipulator arms [40]. When volatile α -emitters are involved, gas-tight enclosures should be considered, and with all α -emitters, double gloving and γ -counter and liquid scintillation should be employed to prevent and monitor contamination [1]. Additionally, radiopharmacies should have a dedicated space for the clinical production of α -emitters, and dedicated α -emitter waste storage.

5. Alpha Emitter Radiochemistry and Targeting

5.1. Radiochemistry and Chelators

Chelating agents that result in the stable coordination of α -emitting radionuclides are important, since a matching radiometal–chelate chemistry is key to success in targeted therapies and avoiding unintended distribution and toxicity to nontarget organs and tissues. Metallic radionuclides have utilized bifunctional chelating agents, which have a metal-binding moiety function that sequesters the metallic radionuclide, and a chemically reactive functional group that covalently attaches a targeting vector such as small molecule peptides, proteins, or nanoparticles. The chelator vector can be attached to the vector either directly or through a linker that is often used to modify pharmacokinetics, which can be a simple hydrocarbon chain or a small peptide sequence. The loss of dissociation of the radiometal is associated with therapeutic toxicity; thus, key coordination chemistry factors to consider include charge, similar ionic radius and chelating cavity size, as well as providing an optimal number of chemically appropriate donor binding groups. [41].

From this, the stability of radiopharmaceuticals for use in α -therapy depends on different characteristics, including the coordination properties of the parent radionuclide, complexation kinetics including time, temperature, pH, the thermodynamic stability of the radionuclide–chelator complex in solution, and the kinetic inertness when competing with other ions and chelating agents. Additional factors that influence radiopharmaceutical quality include radiolytic effects, the recoil effects of the daughters, and the unique chemistry of the various daughter nuclides. Several commonly employed chelators are depicted in Figure 3, and notable chelators that have been investigated with therapeutic α emitters are listed in Table 4.




Figure 3. Several commonly employed radiometal chelators.

Table 4. Chelators for the rapeutic α emitters.

Radionuclide	Commonly Investigated Chelators	References
	DOTA, DOTATOC, DO3A, PEPA, EDTA, CHX-A"-DTPA, HEHA, DOTMP, tu-BU-calix	
²²⁵ Ac	[4]arene-tetracarboxylic acid, macropa, macropa-NCS, H4py4pa, H4octapa, H4CHXoctapa,	[21,26,28,42-45]
	DOTP, crown	
²¹³ Bi	DOTA, DOTATOC, DTPA, CHX-A"-DTPA, DOTP, DOTPH, DOTPOEt, DOTPI, NETA	[28,46]
²¹² Bi	DOTA, DOTMP, DTPA, TCMC, 1B4M-DTPA, CHX-A"-DTPA, NETA	[28,47]
²¹² Pb	DOTA, DTPA, TCMC, EDTA	[27,34,40]
²²⁷ Th	DOTA, DTPA, DTMP, DOTMP, HOPO, octapa me-3,2-HOPO	[28]
²¹¹ At	m-or p-SnMe ₃ -Bz, m-or p-SnBu ₃ -Bz, closo-decaborate, Tin precursors, prosthetic groups	[1,28]
²²³ Ra	No known chelators	[28]
²²⁴ Ra	No known chelators	[28]
¹⁴⁹ Tb	DOTA, DOTANOC, DOTA-folate, DTPA	[36]

5.1.1. ²²⁵Ac

In aqueous solution, ²²⁵Ac is most stable in its +3 oxidation state, with a potential possibility of accessing its +2 oxidation state [48]. Notably, Ac^{3+} is the largest +3 ion on the periodic table, and with a low charge density, it is the most basic +3 ion. Ac³⁺ possesses similar chemical properties to lanthanide Ln³⁺ ions, with lanthanum La³⁺ being a useful Ac³⁺ surrogate for radiochemistry. With its demonstrated ability to stably coordinate hard +3 ions, ²²⁵Ac is stable on coordination by the DOTA chelator and its derivatives [49], and has shown improvements in whole body clearance and decreased organ uptake compared to acyclic ligands such as EDTA and CHX-A" DTPA. Other ligands, such as macropa and macropa-NCS have promise in coordinating ²²⁵Ac, and they showed minimal organ accumulation and remained highly stable in vivo over an extended period of time [50,51]. It has also been suggested that acyclic chelating agents such as linear polyaminocarboxylates are not good ligands for ²²⁵Ac due to high liver uptake and poor whole body clearance resulting from the loss of ²²⁵Ac from these chelating agents [52]. DOTP⁸⁻ has been chelated with ²²⁵Ac, compared with other 3+ cations, including Am, Cm, and La, and verified to be encapsulated within the DOTP⁸⁻ binding pocket [44]. Recently developed ²²⁵Ac chelators such as H₄py4pa and H₄py4pa-phenyl-NCS have demonstrated excellent in vivo stability and tumor specificity [53]. Another novel chelator, ²²⁵Ac-crown, was shown to be stable over an extended period of time, while binding rapidly to ²²⁵Ac at ambient temperature [45].

5.1.2. ²¹³Bi

²¹³Bi is obtained in its +3 oxidation state from a ²²⁵Ac/²¹³Bi generator, and forms stable complexes with nitrogen-rich chelators such as CHX-A"-DTPA or NETA, and is also stable with DOTA [49]. Optimized protocols for ²¹³Bi labelling of antibodies in clinical settings permit the synthesis, sterile filtration, and quality control of therapeutic doses within 15 min of elution from a ²²⁵Ac generator [32]. It has also been found that kinetically inert Bi³⁺ complex formation is very slow [54]. Notably, phosphorus containing ligands DOTP, DOTP^H, DOTP^{Et}, DOTPI were found to match CHX-A"-DTPA and have superior labelling efficiencies to DOTA, with DOTP being the most efficient. They also exhibited excellent stability in human plasma and exhibited a higher stability against demetallation compared to DOTA and CHX-A"-DTPA [46].

5.1.3. ²¹²Bi/²¹²Pb

²¹²Bi has been attached to a variety of acyclic chelators, notably DTPA, EDTA, EDTMP. The parent nuclide ²¹²Pb can be considered preferable to ²¹²Bi since its half-life of 10.64 h is significantly longer than the 60.6 min half-life of ²¹²Bi, permitting up to 10 times more dose per administered activity. Therefore, ligands that stably chelate ²¹²Bi and ²¹²Pb are attractive for employing this nanogenerator approach [54].

5.1.4.²²⁷Th/²²³Ra

²²⁷Th has a +4 oxidation state, and has been studied with ligands that accumulate in bone, including phosphate ligands such as DTMP, DOTMP, and EDTMP. Employing ²²⁷Th is advantageous for obtaining an additional α-decay, compared to just using its ²²³Ra daughter [28]. Although ²²³Ra has a +2 oxidation state, it is highly basic and does not form complexes in aqueous solution. There are no known ²²³Ra chelators, so there is no way to target its accumulation. ²²⁷Th can also be chelated by hydroxopyridinone coordinating moieties, including N-methyl-3,2-hydroxypyridinone (Me-3,2-HOPO) [55].

5.1.5. ²¹¹At

²¹¹At is a halogen, presenting different radiolabeling chemistry than radiometals. In its positive oxidation states, astatine exhibits properties specific to metal ions such as silver in its +1 oxidation state and polonium in its higher oxidation states. In its -1 state, it exhibits characteristics similar to iodine. Slow, low yield electrophilic radiolabeling of nonactivated aromatic rings can lead to ²¹¹At compounds in vivo [28]. Several compounds that have been stable when labeled with ²¹¹At include N-succinimidyl 3-(trimethylstannyl)benzoate and a boron cage compound [56,57]. ²¹¹At can also be radiolabeled by adapting radioiodination chemistry using tin precursors and prosthetic groups [58].

5.1.6. ¹⁴⁹Tb

¹⁴⁹Tb forms +3 and +4 oxidation states and can be chelated with DOTA conjugates [59], and it is particularly attractive since there are no α -emitting progeny presenting a redistribution issue upon release from the chelator. Radiolabeling using bifunctional chelators such as DOTA and DTPA has been well developed, giving a clear advantage over alpha emitters such as ²¹¹At and ²²³Ra [25]. One study using [¹⁴⁹Tb]Tb-DOTANOC achieved high-quality PET images of an AR42J tumor-bearing mouse, demonstrating the exceptional potential of ¹⁴⁹Tb to combine α -therapy with PET in "alpha-PET" using a single radionuclide [59].

5.2. *α Emitter Redistribution*

While α emitters with multiple daughters—in vivo generators—can enhance the delivered dose to a tumor site, they can also redistribute and cause unintended toxic effects. Upon α emission, recoil energy (~100 keV) imparted to a daughter nuclide is at least 1000 times higher than any chemical bond, releasing in at least partial release of the daughter nuclide from the targeting molecule. Redistribution depends on the distance

traversed by the daughter nuclide upon release, diffusion and active transport processes, the half-life of the daughter, and the affinity of the radionuclide for different organs [1]. With redistribution, radioactive burden can be spread across the body, reducing elimination and leading to radiotoxic effects such as organ dysfunction and secondary tumorigenesis. Dosimetry is essential to understand the contributions of a radiolabeled targeting vector, labeled metabolites, liberated mother nuclides, and the daughters released upon recoil [19]. Radionuclide distribution is often measured in postmortem ex vivo organ analysis, using an alpha camera or a timepix detector [19,60–62].

Some α -emitters are prone to redistribution. Redistribution compromised the continuation of a ²²⁴Ra clinical study, with 8% of the ²²⁰Rn daughter nuclide leaving the body and significant ²¹²Pb and ²¹²Bi uptake observed in the red blood cells, kidney, and liver [63]. ²²⁵Ac faces limitations due to the redistribution of the ²¹³Bi daughter to the kidneys, with one study in mice showing 0.77 Gy·kBq⁻¹ of kidney dose after tissue harvest, 60% of which was attributed to nonequilibrium ²¹³Bi [64]. Dose-limiting salivary gland toxicity and reduced salivary gland function have also been observed in clinical studies using ²²⁵Ac-labelled PSMA for treating metastatic castration-resistant prostate cancer [65]. Other α emitters such as ²²³Ra demonstrated low redistribution in mice and humans [66]. ¹⁴⁹Tb shows promise compared to the previously listed α -emitters since it has only one α emission in its decay chain; thus, once ¹⁴⁹Tb radiopharmaceuticals accumulate in their target, they should be less prone to toxic redistribution effects.

Several theories have been proposed to mitigate the consequences of the daughter recoil effect [19]: (1) Since the spread of daughter radionuclides takes time in the body, their spread depends on their physical half-life. With blood flow in capillaries between 1–3 mm/s, daughter nuclei will not undergo significant translocation if their half-lives are short (several seconds). (2) Daughter recoil can be mitigated by nanoconstructs. Encapsulating a radionuclide within the core of a nanoconstruct with sufficient stopping power can significantly mitigate free daughter spread. (3) Even if a recoil daughter escapes a nanoconstruct, it has a high probability of back-implantation into surrounding nanoconstructs [19].

While α emitters with a shorter t_{1/2} are an effective solution to daughter redistribution, the higher cytotoxicity—and therefore therapeutic potential—of radioisotopes with progeny redistribution has motivated developing techniques to control the daughter radionuclides [1]. Nanocarrier encapsulation of α -emitters to contain recoil daughters shows promise, with one method utilizing liposomes. ²²³Ra was encapsulated in pegylated liposomal doxorubicin (PLD) and remained relatively stable in vivo with skeletal uptake lower than free ²²³Ra [67]. Liposomes have also enhanced the retention of ²²⁵Ac daughters [68]. One study used TiO₂ nanoparticles labeled as a carrier for ²²⁵Ac and functionalized with substance P (5–11), a peptide fragment targeting NK1 glioma cell receptors. Leaching of 30% of ²²¹Fr, the first decay daughter of ²²⁵Ac, was observed in cerebrospinal fluid after 10 days, with the complex showing high cytotoxic effects in T98G glioma cells [69]. One study employed ²²⁵Ac gold-coated lanthanide phosphate nanoparticles, where the multishell nanoparticles combined the radiation resistance of lanthanide phosphate, magnetic properties of gadolinium phosphate, and gold chemistry for attaching targeting vectors [70]. Another approach involves diffusing alpha-emitters radiation therapy (DaRT), a new form of brachytherapy, where seeds impregnated with radionuclides are embedded in solid tumor tissue where they continually release α -emitters [71].

An additional method to reduce toxic renal effects of ²²⁵Ac daughters involves metal chelation therapy and diuretics. In animals, oral metal chelation with dithiols was shown to reduce renal ²¹³Bi activity, and furosemide and chlorothiazide significantly reduced ²²¹Fr renal activity [72].

Pretargeting also shows potential for both PET imaging and for reducing nonspecific toxicity and hematotoxicity in radioimmunotherapy. This is where an unlabeled immunoconjugate capable of binding a tumor specific antigen is injected prior to a small molecular weight payload that then binds to the immunoconjugate [73].

6. Preclinical Studies and Clinical Applications

There are numerous preclinical and clinical studies of α -emitting radiopharmaceuticals completed or underway for a variety of cancers, which are outlined in Table 5.

Table 5. Preclinical investigations and clinical applications of α -emitting radiopharmaceuticals.

Cancer Type	α -Emitting Radiopharmaceutical			
Cancer Type	Preclinical Clinical		Reference	
Colorectal cancer	²¹³ Bi-labeled CO-1A Fab', ²²⁴ Ra diffusing alpha emitters radiation therapy (DaRT)	²²⁴ Ra (Radspherin [®])	[74]	
Neuroendocrine	[²²⁵ Ac]Ac-DOTATOC	[²¹³ Bi]Bi-DOTATOC, [²¹² Pb]Pb-DOTAMTATE, [²²⁵ Ac]Ac-DOTATOC	[74–76]	
Multiple myeloma	²¹³ Bi-labeled 9.E7.4 anti-CD138 mAb, [²²⁵ Ac]Ac-BC8, [²¹¹ At]At-CD38	[²²⁵ Ac]Ac-lintuzumab	[74,77]	
Breast cancer	[²²⁵ Ac]Ac-7.16.4 anti-rat HER-2/neu, [²¹² Pb]Pb-labeled 225.28 antibodies,	²²⁴ Ra (DaRT), ²²⁷ Th-antibody	[74,78]	
Metastatic castration resistant prostate cancer	[²¹³ Bi]Bi-DOTA-PESIN	[²²⁵ Ac]Ac-PSMA617, [²²³ Ra]Ra-dichloride (Xofigo), [²²⁷ Th]Th-PSMA antibody	[74,79,80]	
Peritoneal carcinoma	[²¹³ Bi]Bi-d9MAb	²²⁴ Ra (Radspherin [®])	[74]	
Glioblastoma	[²²⁵ Ac]Ac-E4G10	[²¹³ Bi]Bi-DOTA-substance P, [²¹¹ At]At-ch81C6	[81-83]	
Lymphoma	[²¹³ Bi]Bi-DOTA-biotin, [²²⁷ Th]Th-rituximab, [²²⁷ Th]Th-epratuzumab		[84,85]	
Leukemia	[²¹³ Bi]Bi-lintuzumab, [²²⁷ Th]Th-lintuzumab, [¹⁴⁹ Tb]Tb-rituximab	[²²⁵ Ac]Ac-anti-CD33 HUM195, [²²⁵ Ac]Ac-lintuzumab, [²¹³ Bi]Bi-HuM195, [²¹¹ At]At-BC8-B10	[3,86,87]	
Skeletal cancers and		²²³ Ra, ²²⁴ Ra	[88,89]	
bone metastases Ovarian cancer		²²⁴ Ra (Radspherin [®]), [²¹² Pb]Pb-TCMC-trastuzumab		
Pancreatic cancer Lung cancer Synovial Sarcoma	 ²¹²Pb-labeled 376.96 mAb [²¹¹At]At-SPC-octerotide [²¹¹At]At-OTSA101 	²²⁴ Ra (DaRT),	[90] [91] [92]	
Advanced Refractory		[²²⁵ Ac]Ac-FPI-1434		
Solid tumors Bladder Carcinoma Melanoma	[²²⁵ Ac]Ac-crown-αMSH	[²¹³ Bi]Bi-anti-EGFR mAb	[93] [45]	
Squamous cell carcinoma		²²⁴ Ra (DaRT)	[94]	

6.1. Preclinical Studies

Since α -emitters have the potential for high efficacy but also high toxicity, preclinical studies, in vivo and in vitro, are essential for optimizing α -therapy and guiding further clinical trials. Some notable preclinical studies using a variety of α -emitters are outlined below.

6.1.1. ²²⁵Ac

Figure 4 shows MRI images of [²²⁵Ac]Ac-E4G10-treated glioblastoma-bearing mice, demonstrating the clear tumor growth control effected by the treatment. Metastatic prostate cancer is of interest for TAT due to the external domain of the prostate-specific membrane antigen (PSMA). ²²⁵Ac has been used with PSMA compounds such as PSMA-617 for prostate cancer therapy. One study in PC-3/PC-3-PIP-tumor-bearing mice compared the effects of [¹⁷⁷Lu]Lu-PSMA617 with [²²⁵Ac]Ac-PSMA617, finding improved overall antitumor effectiveness and enhanced therapeutic efficacy for [²²⁵Ac]Ac-PSMA-617 [79]. CD-45

antigens are found on all immune cells, including hematopoietic stem cells and precursor and mature lymphoid and myeloid cells, giving potential for radiotherapy of leukemia and lymphoma. Anti-CD45 radioconjugates labeled with ²²⁵Ac, such as [²²⁵Ac]Ac-BC8, have demonstrated effective tumor control in mice bearing multiple myeloma tumors, with modest uptake in the kidney and significant uptake in the liver [77]. Human epidermal growth factor receptor type 2 (HER2) is overexpressed in carcinomas; thus, HER2 antibodies and nanobodies have been investigated for radioimmunotherapy. ²²⁵Ac-labeled nanobodies such as [²²⁵Ac]Ac-DOTA-Nb have shown fast uptake in tumor-bearing mice with HER2-overexpressing tumors, with coinjection of Gelofusine reducing kidney retention by 70% [95]. TAT can also target the tumor microenvironment, such as the vasculature and neovascular endothelium. One study using a [²²⁵Ac]Ac-E4G10 antibody conjugate that targets the vascular endothelium of glioblastoma demonstrated tumor growth control and improved survival in a mouse [81].




Figure 4. (**A**) Tumor sizes of control and [²²⁵Ac]Ac-E4G10 treated glioblastoma-bearing mice before and after 10 days, imaged by MRI. (**B**) Mean tumor volumes for control and [²²⁵Ac]Ac-E4G10-treated mice. Reproduced from [81], JNM, 2016.

6.1.2. ²¹³Bi

Figure 5 depicts the survival curve of mice treated with ²¹³Bi-9E7.4 anti-CD138 antibodies compared to a control group. ²¹³Bi has been shown to be more effective than ¹⁷⁷Lu in animal models for treatment of multiple myeloma (MM). Using ²¹³Bi-labeled 9E7.4 anti-CD138 antibodies in mice with 5T33 MM cells, mean survival was significantly increased significantly and a cure was effected in 45% of animals. ¹⁷⁷Lu-labeled 9E7.4 anti-CD138 antibodies increased survival to a lesser degree than the ²¹³Bi, with no mice cured [96]. [²¹³Bi]Bi-DOTA-biotin has been used to target non-Hodgkin lymphoma when pretargeted with an anti-CD20 fusion protein. Mice with Ramos lymphoma xenografts exhibited significant delayed tumor growth and no treatment-related mortalities [84]. Another study in mice with intramuscular LNCaP xenografts used ²¹³Bi conjugated to a J591 anti-PSMA monoclonal antibody, which resulted in improved tumor-free survival, effectively stopped the growth of LNCaP spheroids, and reduced prostate-specific antigen levels [97].

6.1.3. ²²³Ra.

The antitumor effects of ²²³Ra have been demonstrated extensively in animal models, leading to commercial use of this radium isotope in men with metastatic prostate cancer, where it has improved overall survival and reduced the time until the first symptomatic skeletal event [98]. ²²³Ra was investigated in an experimental skeletal metastases model in nude rats that received human breast cancer cells. The animals treated with ²²³Ra




Figure 5. Survival curve of mice injected with 5T33 cells at day 0. 3.7 MBq of ²¹³Bi-9E7.4 antibodies was injected for alpha therapy (n = 20), and NaCl was injected into the control group (n = 44). Reproduced from [96], Frontiers, 2015.

6.1.4. ²²⁴Ra

²²⁴Ra is similar to ²²³Ra with its tendency to adsorb to bone at sites of active mineral crystallization, and inability to be stably bound to a targeting molecule vector. Calcium carbonate microparticles have been proposed as ²²⁴Ra carriers for treatment of disseminated cancers, such as in those occurring in the peritoneum. One study demonstrated high labelling efficiencies of ²²⁴Ra on the surface of calcium carbonate microparticles with high retention of both ²²⁴Ra and its ²¹²Pb daughter, and the radioactivity remained primarily localized in the peritoneal cavity [89]. ²²⁴Ra has also been investigated for osteolytic bone metastasis of MDA-MB-231(SA)-GFP-bearing nude mice, decreasing the number and area of tumor foci and prolonging survival [99]. Preclinical diffusing alpha emitters therapy (DaRT) using ²²⁴Ra-loaded wires was tested on mice bearing prostate (PC-3), glioblastoma (GBM, U87-MG), colon (HCT15), squamous cell carcinoma (FaDu), and melanoma (C32) cancer cell tumors. The in vivo study confirmed that DaRT can destroy tumors, with only the C32 cells exhibiting resistance [100].

6.1.5. ²¹²Pb

The ²²⁴Ra daughter ²¹²Pb has been used in a variety of preclinical trials. ²¹²Pblabeled 376.96 monoclonal antibodies were used in mice bearing pancreatic cancer Panc039 xenografts, exhibiting significant uptake and tumor growth inhibition compared to an existing [²¹²Pb]Pb-F3-C25 compound [90]. ²¹²Pb-labeled 225.28 antibodies were used in immune-deficient mice bearing SUM159 and 2LMP human triple-negative breast cancer cells, showing high cell uptake and effective inhibition of tumor growth for CSPG4expressing tumors [78]. Recently, a variety of low molecular weight ligands were developed and labeled with ²¹²Pb, and investigated in PSMA(+) PC3 PIP and PSMA(-) PC3 flu flank xenografts. Several of the labeled ligands demonstrated antitumor efficacy, with the kidneys discovered to be the dose-limiting organ [101]. Internalizing and non-internalizing antibodies can have different outcomes. Using internalizing ²¹²Pb-labeled trastuzumab and non-internalizing [²¹²Pb]Pb-35A7 in mice with intraperitoneal A-431 cell tumor xenografts, the non-internalizing conjugate led to higher tumor dose, while the internalizing led to longer mean survival. This demonstrates the potential advantage of using internalizing TAT [102]. ²¹²Pb-labeled NG001, a PSMA ligand, was investigated in mice bearing C4-2 tumors, demonstrating a 2.5-fold lower kidney uptake compared to [²¹²Pb]Pb-PSMA-617. This was attributed to the NG001 chelator having all four arms available due to the use of a backbone linker, instead of using a chelator arm for the linking purpose. [103].

6.1.6. ²²⁷Th

²²⁷Th has been conjugated to antibodies including trastuzumab, rituximab, and has demonstrated a significant delay in tumor growth and prolonged survival in breast, ovarian, and lymphoma models [3]. [²²⁷Th]Th-rituximab was investigated in mice with human lymphoma Raji xenografts. The maximum tolerated dose was found to be 600–1000 kBq/kg, with a 1000 kBq/kg dose resulting in significant weight loss and temporary drop in white blood cell and platelet counts, with no significant signs of toxicity in examined tissue [85]. Lintuzumab, an anti-CD33 antibody, has been used extensively in TAT for treatment of myeloid leukemia, and has been conjugated to ²¹³Bi, ²²⁵Ac, and ²²⁷Th. [3]. [²²⁷Th]Th-lintuzumab induced cytotoxicity in CD33-positive cells and demonstrated antitumor activity in a HL-60 cell mouse model with a single dose regimen [86].

6.1.7. ²¹¹At

²¹¹At has been investigated for non-small cell lung cancer using an ²¹¹At-labeled octreotide somatostatin analogue. In mice, [²¹¹At]At-SPC-octreotide exhibited higher uptake in the lung, spleen, stomach, and intestines with rapid clearance 24 h post-injection, while demonstrating tumor cell apoptosis in a dose-dependent manner [91]. ²¹¹At-labeled anti-Frizzled homolog 10 antibody, [211At]At-OTSA101, has been shown to suppress the growth of synovial sarcoma xenografts in mice with greater efficiency than β^- emitter ^{[90}Y]Y-OTSA101 [92]. Anti-HER2 single domain antibodies and nanobodies have been evaluated, with iso-[²¹¹At]At-SAGMB-5F7 demonstrating high intracellular trapping of radioactivity and greater than 10:1 tumor-to-normal organ ratios except for the kidneys and lungs by 2 h post-injection [104]. Another compound, [²¹¹At]At-SAGMB-2Rs15d, demonstrated high tumor uptake, low background signals, and fast renal excretion [105]. ²¹¹At has also been conjugated to anti-CD38 and anti-CD45 antibodies. ²¹¹At-CD38 produced a sustained remission and long-term survival (>150 days) for 50 to 80% of mice with multiple myeloma xenografts, compared to untreated mice dying in 20 to 55 days [106]. [²¹¹At]At-anti MICA/B antibodies have shown significant reduction in the tumor growth rate of HCT116 $p53^{-/-}$ xenografts in mice. Systemic cancers such as B-cell lymphoma can be treated by targeting the CD20 surface antigen [107].6.1.8. ¹⁴⁹Tb

Figure 6 depicts PET/CT images of an AR42J tumor-bearing mouse after injection with [¹⁴⁹Tb]Tb-DOTANOC. ¹⁴⁹Tb was first used in a SCID mouse model of leukemia with ¹⁴⁹Tb-labeled rituximab. In total, 89% of treated mice experienced tumor-free survival of over 4 months, a significant increase compared to other groups [108]. Since then, the ¹⁴⁹Tb-labeled DOTA–folate conjugate has been evaluated in folate receptor (FR)-positive cancer in KB-tumor-bearing mice, with an observed dose-dependent effect, significant tumor growth delay, and no signs of acute toxicity to the kidneys or liver [36]. ¹⁴⁹Tb is also a positron emitter; thus, it was investigated for its utility in PET imaging using [¹⁴⁹Tb]Tb-DOTANOC in a mouse with AR42J tumor xenografts, producing distinct visualization of the tumors with residual radioactivity in the kidneys and bladder [59]. The potential for ¹⁴⁹Tb alpha-PET would make it attractive for clinical applications, allowing the direct visualization of therapeutic ¹⁴⁹Tb; additional preclinical studies and increased supply sources may enable future clinical trials.

6.2. Clinical Studies

In the past decade, there has been a large increase in TAT clinical trials using an array of α -emitters for treating a variety of cancers. Notably, many trials listed on clinical-trials.gov



coronal

transaxial

Tb 149

are currently underway, recruiting, or are not yet open for recruitment. A summary of completed trials and those underway or about to begin is given in this section.

Figure 6. (**A**,**B**) Maximal intensity projections and (**C**) sections of positron emission tomography (PET)/CT images of an AR42J tumor-bearing mouse 2h after injection with 7 MBq of [¹⁴⁹Tb]Tb-DOTANOC. Reproduced from [59], Frontiers, 2017.

sagittal

MIP

6.2.1. ²²⁵Ac

Figure 7 depicts the results from [²²⁵Ac]Ac-PSMA-617 therapy in a human patient, which overcame tumor resistance to [¹⁷⁷Lu]Lu-PSMA-617. There are nine clinical trials listed on clinical-trials.gov for ²²⁵Ac, one of which is a completed phase 1 trial using ²²⁵Aclabeled humanized anti-CD33 HuM195 antibodies for advanced myeloid malignancies including leukemia and myelodysplastic syndrome. ²²⁵Ac was considered as an alternative to ²¹³Bi for its greater cytotoxic potential and longer half-life. [²²⁵Ac]Ac-HuM195 eliminated peripheral blasts in 63% of patients at doses of 37 kBq/kg or higher, and reduced bone marrow blasts in 67% of patients [87]. ²²⁵Ac salvage therapy overcame β^- resistance in two metastatic-CRPC patients after a PSMA-positive tumor phenotype was verified by [68Ga]Ga-PSMA-11 PET/CT. Both patients exhibited a complete response, and PSA dropped below the measurable level, with side effects of xerostomia observed in both patients. A further study with 14 metastatic CRPC patients identified 100 kBq/kg to be an appropriate balance between toxicity and antitumor activity [16]. While [¹⁷⁷Lu]Lu-PSMA-617 has improved overall survival of CRPC patients, it has been suggested that further studies with ²²⁵Ac PSMA compounds will elucidate their distinct advantages over β^- therapy with ¹⁷⁷Lu [109,110]. A pilot study using [²²⁵Ac]Ac-PSMA-617 in patients heavily pretreated with chemotherapy led to a greater than 90% decline in PSA serum in 82% of patients, including 41% of patients with undetectable serum PSA who remained in remission 12 months after therapy [111]. A more recent study reported a single cycle of [²²⁵Ac]Ac-DOTATOC achieving a partial remission in a patient with refractory metastatic neuroendocrine tumors without any adverse effects after resistance to 10 cycles of the β^- -emitters [¹⁷⁷Lu]Lu-DOTATATE and [⁹⁰Y]Y-DOTATOC [76]. Ongoing trials with ²²⁵Ac include a phase 1 study of [²²⁵Ac]Ac-lintuzumab in patients with refractory multiple myeloma; an early phase 1 trial of [225Ac]Ac-PSMA radioligand therapy of metastatic castration-resistant prostate cancer; a phase 1 study that targets type I insulin-like growth factor receptor using [²²⁵Ac]Ac-FPI-1434 injection for patients with advanced refractory solid tumors; an early phase 1 trial of [²²⁵Ac]Ac-PSMA radioligand therapy of metastatic castration-resistant prostate cancer; a phase 1 and 2 trial with [²²⁵Ac]Ac-lintuzumab in

older acute myeloid leukemia patients; a phase 1 trial using [²²⁵Ac]Ac-lintuzumab in combination with CLAG-M chemotherapy in patients with relapsed/refractory acute myeloid leukemia; a phase 1 and 2 trial of venetoclax and [²²⁵Ac]Ac-lintuzumab in acute and relapsed myeloid leukemia patients; and a phase 1 and 2 trial venetoclax, azacytidine, and [²²⁵Ac]Ac-lintuzumab in acute myeloid leukemia patients.




Figure 7. [⁶⁸Ga]Ga-PSMA-11 PET/CT scans of a patient with castration-resistant prostate cancer (CRPC). (**A**) Initial tumor burden (**B**) Progression despite 2 cycles of β^- -emitting [¹⁷⁷Lu]Lu-PSMA-617 (**C**,**D**) Impressive decrease in tumor burden after two cycles of α -emitting [²²⁵Ac]Ac-PSMA-617. Reproduced from [6], Frontiers, 2014.

6.2.2. ²¹³Bi

Figure 8 depicts the significant therapeutic efficacy of [²¹³Bi]Bi-DOTATOC on liver metastases in a patient. [²¹³Bi]Bi-DOTATOC has been used for β^- radiation–refractory tumors in patients with advanced neuroendocrine tumors and liver metastasis who were pretreated with β⁻ emitting [⁹⁰Y]Y-DOTATOC and [¹⁷⁷Lu]Lu-DOTATOC. [²¹³Bi]Bi-DOTATOC was administered with increasing activity in cycles every 2 months, with patients overcoming β^{-} radiation resistance and showing long-lasting antitumor response. Renal toxicity was minimized by administering lysine, arginine, and Gelofusine as developed for $\beta^$ therapy [75]. Advanced myeloid leukemia has been treated with [²¹³Bi]Bi-HuM195, with doses from 10.4-37 MBq/kg. Although patients developed transient myelosuppression, no extramedullary toxicity was observed. However, no patient achieved complete remission, likely due their large tumor burdens. [²¹³Bi]Bi-DOTA-substance P has been used in a study with 20 patients with recurrent glioblastoma, with only mild and transient adverse reactions and a median survival after recurrence of 10.9 months [82]. Another study used ²¹³Bi-labeled anti-EGFR monoclonal antibodies in patients with carcinoma in situ of the bladder, achieving complete remission in 3 of 12 patients with no adverse effects observed and blood and urine parameters remaining in normal ranges [93].

6.2.3. ²²³Ra

Having received FDA approval in May 2013 to treat castration-resistant prostate cancer under the name Xofigo, ²²³Ra-dichloride has been studied extensively, with 108 listed clinical trials on the clinicaltrials.gov website. ²²³Ra-dichloride resulted in pain relief and a reduction in alkaline phosphatase in the first clinical trial in patients with skeletal metastases. Over 50% of patients reporting pain relief 8 weeks after injection, and median survival exceeded 20 months [112]. One ²²³Ra-dichloride phase III trial with 921 patients found that the time to first symptomatic skeletal event (15.6 months) was

significantly longer compared to the placebo group (9.8 months). The risks of external beam radiation therapy for bone pain and spinal cord compression were also found to be reduced [113]. Another study in CRPC patients found overall survival was significantly longer with ²²³Ra-dichloride at 14.9 months compared to 11.3 months with a placebo. ²²³Ra treatment was associated with low myelosuppression and reduced adverse events. [114]. These studies collectively found that ²²³Ra-dichloride is well tolerated and minimally toxic, and patients have reported an increase in quality of life. Despite these benefits, ²²³Ra does not target soft tissue or circulating disease components [3]. However, in 2018, the European Medicines Agency recommended restricting the use of Xofigo to patients who had two previous treatments for metastatic prostate cancer, or who could not receive other treatments. The agency concluded that Xofigo should not be used in combination with Zytiga, prednisone, or prednisolone, since it was observed to reduce survival and lead to additional bone fractures in patients also taking Zytiga [115].




Figure 8. (a) Patient with an extensive liver metastases tumor burden imaged with [⁶⁸Ga]Ga-DOTATOC. (b) After injection of 10.5 GBq of [²¹³Bi]Bi-DOTATOC, liver metastases shrunk significantly. Reproduced from [75], Springer, 2014.

6.2.4. ²²⁴Ra

Figure 9 depicts a complete response to squamous cell carcinoma of the scalp using DaRT and a Kaplan-Meier plot of progression-free survival stratified by complete and partial response. There are currently eleven ²²⁴Ra clinical trials listed on clinicaltrials.gov. Nine of these trials are utilizing diffusing alpha radiation emitters therapy for the treatment of skin cancer, mucosal neoplasms of the oral cavity, soft tissue neoplasms, pancreatic cancer, squamous cell carcinoma, and breast cancer. The other two trials are using Radspherin[®], which consists of a ²²⁴Ra α -emitting calcium carbonate microsphere for patients with peritoneal carcinoma, colorectal carcinoma, and ovarian cancer. A recent DaRT study used ²²⁴Ra seeds to treat squamous cancers of the skin and head and evaluated early tumor responses 30 to 45 days post insertion, with complete response to the treatment observed in 22 of 28 patients [94].

6.2.5. ²¹²Pb

There are two clinical trials listed for ²¹²Pb, with a phase 1 safety study using [²¹²Pb]Pb-TCMC-trastuzumab in patients with HER2-expressing ovarian cancer confined to the peri-

toneal cavity. After intraperitoneal injection, minimal myelosuppression and radiopharmaceutical redistribution outside the peritoneal cavity were observed; however, no patient exhibited a partial response [116]. The other trial is a phase 1 study using AlphaMedixTM ([²¹²Pb]Pb-DOTAMTATE) in patients with metastatic somatostatin-receptor-positive neuroendocrine tumors.




Figure 9. (a) Deeply infiltrating squamous cell carcinoma of the scalp showing complete response to diffusing alpha emitters therapy (DaRT) by day 30. (b) Kaplan-Meier local progression-free survival stratified by complete and partial response. Reproduced with permission from Popovtzer, A., published by Elsevier, 2020 [94].

6.2.6. ²²⁷Th

There are four clinical trials using ²²⁷Th listed. They include a phase 1 trial using the thorium labeled PSMA-TTC (BAY 2315497) immunoconjugate consisting of a human anti-PSMA antibody covalently linked to the chelator moiety (3,2 HOPO) radiolabeled to ²²⁷Th for use in patients with metastatic castration resistant prostate cancer [80]; a phase 1 trial using the ²²⁷Th-labeled antibody–chelator conjugate MSLN-TTC (BAY 2287411) in patients with mesothelin expressing tumors; and a phase 1 study using the ²²⁷Th-labeled antibody BAY2701439 in patients with breast, gastric, gastroesophageal, and other cancers expressing HER2. The fourth, a now complete phase I trial, used [²²⁷Th]Th-epratuzumab (BAY1862864) in patients with relapsed or refractory CD-22-positive non-Hodgkin lymphoma.

6.2.7. ²¹¹At

There are multiple ²¹¹At clinical trials, with a phase I and II trial using [²¹¹At]Atlabeled BC8-B10 monoclonal antibodies for the treatment of nonmalignant diseases in patients undergoing hematopoietic cell transplant, two trials both in phase I and II using [²¹¹At]At-labeled BC8-B10 antibodies in patients with high-risk myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome [117], or mixed-phenotype acute leukemia, and a completed trial with 18 patients using the ²¹¹At-labeled ch81C6 antibody with primary or metastatic brain tumors. In this trial, no patients experienced doselimiting toxicity, there was no identified maximum tolerated dose, and median survival increased to 54.1 weeks from 23 weeks. Another clinical trial evaluated the absorbed dose and investigated the toxicity of [²¹¹At]At-MX35 F(ab')². It targeted the sodiumdependent phosphate transport protein 2b in patients with complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma. This trial established that intraperitoneal administration of [²¹¹At]At-MX35 F(ab')² could achieve therapeutic doses without significant toxicity in microscopic tumor clusters [118].

7. Future of Alpha Therapy

The future of α -therapy holds significant promise for therapeutic clinical applications. Key to its ongoing success is the expansion of robust and high-yield production routes to enhance α -emitter availability, the development of new chelators, linkers, and vectors to enhance efficacy and targeting specificity, and finding solutions to progeny redistribution induced toxicity.

With additional α -emitter production, larger scale preclinical and clinical trials with α emitters should become possible. The construction of new high-energy particle accelerators should also support more preclinical studies and clinical trials of the appealing ¹⁴⁹Tb α -emitter. This could lead to more widespread use of TAT beyond FDA approved ²²³Radichloride, enabling the targeting of a wide range of soft tissue and circulatory disease components.

Controlling the progeny is a challenge with existing α -emitters. Despite the ability to deliver significant dose through a nanogenerator approach, the cytotoxic effects of α -emitter progeny in the ²²⁵Ac, ²²⁷Th, ²²⁴Ra, and ²¹¹At decay chains have shown that balancing tolerable dose with cytotoxic effects can be difficult to achieve. Some solutions to control the daughters or hasten their excretion have included radionuclide impregnated wires, cellular internalization, nanocarriers, metal chelation therapy, and diuretics. Alternatively, the absence of α -emitters progeny in the ¹⁴⁹Tb decay chain could warrant its preference over currently employed α -emitters once its availability improves.

TAT would also benefit from more investigation into dosimetry and radiobiology. Given the majority of DNA lesions along an α -particle path are double strand breaks, this differentiates α -therapy from other classes of therapeutic radionuclides that primarily cause single strand breaks and can be rendered ineffective due to cellular adaptative and resistance mechanisms. Determining an effective microdosimetry method and improving the understanding of α -emitter radiobiology is important for optimizing their efficacy and safe clinical implementation.

8. Conclusions

The short-range high LET characteristics of α -emitter radiotherapy hold promise in being an effective therapy for a variety of cancers. The highly cytotoxic DNA doublestrand breaks and secondary cross-dose and bystander effects give α -emitters a formidable advantage over other forms of radiotherapy, including β^- or auger electron therapy. Supported by ongoing in vitro and in vivo advances in radiochemistry and efficacy in preclinical models, existing clinical trials have demonstrated its feasibility in patients with many additional clinical trials underway or scheduled to start soon. To date, α emitting isotopes have been delivered in free form, with targeting vectors or carriers designed to target specific receptors on cells and limit the spread of the daughters, and the more recent DaRT approach of implantable controlled release. Despite uncertainties in α -therapy regarding optimal patient dose and unintended organ toxicity, preclinical animal models have demonstrated marked improvements. Further advances in production and availability, along with management of the radionuclide progeny, should allow for the development and more cost-effective clinical adoption of TAT. There is immense potential for TAT to complement existing forms of therapy and improve the treatment options and quality of life of patients with highly resistant and late-stage diseases.

Author Contributions: B.J.B.N. prepared the manuscript draft, B.J.B.N., J.D.A., and F.W. performed review and editing, and J.D.A. and F.W. provided supervision. All authors have read and agreed to the published version of the manuscript.

Funding: The authors would like to thank the Dianne and Irving Kipnes Foundation for supporting this work.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Poty, S.; Francesconi, L.C.; McDevitt, M.R.; Morris, M.J.; Lewis, J.S. α-Emitters for radiotherapy: From basic radiochemistry to clinical studies—Part 1. *J. Nucl. Med.* **2018**, *59*, 878–884. [CrossRef]
- Yeong, C.H.; Cheng, M.-H.; Ng, K.H. Therapeutic radionuclides in nuclear medicine: Current and future prospects. J. Zhejiang Univ. Sci. B 2014, 15, 845–863. [CrossRef]
- 3. Poty, S.; Francesconi, L.C.; McDevitt, M.R.; Morris, M.J.; Lewis, J.S. α-Emitters for radiotherapy: From basic radiochemistry to clinical studies—Part 2. *J. Nucl. Med.* **2018**, *59*, 1020–1027. [CrossRef]
- 4. Sollini, M.; Marzo, K.; Chiti, A.; Kirienko, M. The five "W"s and "How" of targeted alpha therapy: Why? Who? What? Where? When? and How? *Rend. Fis. Acc. Lincei* **2020**, *31*, 231–247. [CrossRef]
- 5. Ku, A.; Facca, V.J.; Cai, Z.; Reilly, R.M. Auger electrons for cancer therapy—A review. *EJNMMI Radiopharm. Chem.* **2019**, *4*, 1–36. [CrossRef]
- 6. Elgqvist, J.; Frost, S.; Pouget, J.-P.; Albertsson, P. The potential and hurdles of targeted alpha therapy—Clinical trials and beyond. *Front. Oncol.* **2014**, *3*, 324. [CrossRef] [PubMed]
- Emmett, L.; Willowson, K.; Violet, J.; Shin, J.; Blanksby, A.; Lee, J. Lutetium177PSMA radionuclide therapy for men with prostate cancer: A review of the current literature and discussion of practical aspects of therapy. *J. Med. Radiat. Sci.* 2017, 64, 52–60. [CrossRef] [PubMed]
- 8. Das, S.; Al-Toubah, T.; El-Haddad, G.; Strosberg, J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. *Expert Rev. Gastroenterol. Hepatol.* 2019, *13*, 1023–1031. [CrossRef] [PubMed]
- 9. Kassis, A.I. Molecular and cellular radiobiological effects of Auger emitting radionuclides. *Radiat. Prot. Dosim.* 2010, 143, 241–247. [CrossRef]
- Capello, A.; Krenning, E.; Bernard, B.; Reubi, J.-C.; Breeman, W.; de Jong, M. 111In-labelled somatostatin analogues in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy. *Eur. J. Nucl. Med. Mol. Imaging* 2005, 32, 1288–1295. [CrossRef]
- Li, L.; Quang, T.S.; Gracely, E.J.; Kim, J.H.; Emrich, J.G.; Yaeger, T.E.; Jenrette, J.M.; Cohen, S.C.; Black, P.; Brady, L.W. A phase II study of anti–epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. *J. Neurosurg.* 2010, 113, 192–198. [CrossRef] [PubMed]
- Neshasteh-Riz, A.; Mairs, R.J.; Angerson, W.J.; Stanton, P.D.; Reeves, J.R.; Rampling, R.; Owens, J.; Wheldon, T.E. Differential cytotoxicity of [1231]IUdR, [1251]IUdR and [1311]IUdR to human glioma cells in monolayer or spheroid culture: Effect of proliferative heterogeneity and radiation cross-fire. *Br. J Cancer* 1998, 77, 385–390. [CrossRef] [PubMed]
- 13. Humm, J.L.; Cobb, L.M. Nonuniformity of tumor dose in radioimmunotherapy. J. Nucl. Med. 1990, 31, 75–83. [PubMed]
- 14. Nikula, T.K.; McDevitt, M.R.; Finn, R.D.; Wu, C.; Kozak, R.W.; Garmestani, K.; Brechbiel, M.W.; Curcio, M.J.; Pippin, C.G.; Tiffany-Jones, L.; et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. *J. Nucl. Med.* **1999**, *40*, 166–176.
- 15. Dong, Z.; Tan, Z.; Chen, P.; Schneider, N.; Glover, S.; Cui, L.; Torgue, J.; Rixe, O.; Spitz, H.B. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. *Int. J. Oncol.* 2012, 40, 1881–1888. [CrossRef]
- Kratochwil, C.; Bruchertseifer, F.; Giesel, F.L.; Weis, M.; Verburg, F.A.; Mottaghy, F.; Kopka, K.; Apostolidis, C.; Haberkorn, U.; Morgenstern, A. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. *J. Nucl. Med.* 2016, *57*, 1941–1944. [CrossRef]
- Chan, H.S.; Konijnenberg, M.W.; Daniels, T.; Nysus, M.V.; Makvandi, M.; De Blois, E.; Breeman, W.A.P.; Atcher, R.W.; de Jong, M.; Norenberg, J.P. Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine. *EJNMMI Res.* 2016, *6*, 1–11. [CrossRef]
- Chan, H.S.; de Blois, E.; Morgenstern, A.; Bruchertseifer, F.; de Jong, M.; Breeman, W.; Konijnenberg, M. In vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. *PLoS ONE* 2017, 12, e0181473. [CrossRef]
- 19. Kozempel, J.; Mokhodoeva, O.; Vlk, M. Progress in targeted alpha-particle therapy. What we learned about recoils release from in vivo generators. *Molecules* **2018**, *23*, 581. [CrossRef]
- 20. Sonzogni, A.; Shu, B. Nudat 2.8 (Nuclear Structure and Decay Data). 2020. Available online: Nndc.bnl.gov (accessed on 8 September 2020).
- 21. Scheinberg, D.A. Actinium-225 in targeted alpha-particle therapeutic applications. Curr. Radiopharm. 2011, 4, 306–320. [CrossRef]
- 22. Wood, V.; Ackerman, N.L. Cherenkov light production from the α-emitting decay chains of 223Ra, 212Pb, and 149Tb for cherenkov luminescence imaging. *Appl. Radiat. Isot.* **2016**, *118*, 354–360. [CrossRef] [PubMed]
- 23. Allen, B.J.; Blagojevic, N. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149. *Nucl. Med. Commun.* **1996**, *17*, 40–47. [CrossRef] [PubMed]
- 24. Müller, C.; Domnanich, K.A.; Umbricht, C.A.; Van Der Meulen, N.P. Scandium and terbium radionuclides for radiotheranostics: Current state of development towards clinical application. *Br. J. Radiol.* **2018**, *91*, 20180074. [CrossRef] [PubMed]
- Moiseeva, A.N.; Aliev, R.A.; Unezhev, V.N.; Zagryadskiy, V.A.; Latushkin, S.T.; Aksenov, N.V.; Gustova, N.S.; Voronuk, M.G.; Starodub, G.Y.; Ogloblin, A.A. Cross section measurements of 151Eu(3He,5n) reaction: New opportunities for medical alpha emitter 149Tb production. *Sci. Rep.* 2020, *10*, 1–7. [CrossRef]

- Robertson, A.K.H.; Ramogida, C.F.; Schaffer, P.; Radchenko, V. Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences. *Curr. Radiopharm.* 2018, 11, 156–172. [CrossRef]
- 27. Yong, K.; Brechbiel, M.W. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! *Dalton Trans.* 2011, 40, 6068–6076. [CrossRef]
- 28. Ferrier, M.G.; Radchenko, V. An appendix of radionuclides used in targeted alpha therapy. *J. Med. Imaging Radiat. Sci.* 2019, 50, S58–S65. [CrossRef]
- 29. Zalutsky, M. Astatine-211: Production and availability. Curr. Radiopharm. 2011, 4, 177-185. [CrossRef]
- 30. Nolan, J.; Mustapha, B.; Gott, M.; Washiyama, K.; Sampathkumaran, U.; Winter, R. Development of 211At production via continuous extraction of 211Rn. *J. Med. Imaging Radiat. Sci.* **2019**, *50*, S107. [CrossRef]
- Zaitseva, N.G.; Dmitriev, S.N.; Maslov, O.D.; Molokanova, L.G.; Starodub, G.Y.; Shishkin, S.V.; Shishkina, T.V.; Beyer, G.J. Terbium-149 for nuclear medicine. The production of 149Tb via heavy ions induced nuclear reactions. *Czechoslov. J. Phys.* 2003, 53, A455–A458. [CrossRef]
- 32. Morgenstern, A.; Apostolidis, C.; Kratochwil, C.; Sathekge, M.; Krolicki, L.; Bruchertseifer, F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. *Curr. Radiopharm.* **2018**, *11*, 200–208. [CrossRef] [PubMed]
- 33. Engle, J.W. The production of Ac-225. Curr. Radiopharm. 2018, 11, 173–179. [CrossRef] [PubMed]
- Yong, K.; Brechbiel, M.W. Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and mechanistic understanding through to clinical translation. *AIMS Med. Sci.* 2015, 2, 228–245. [CrossRef] [PubMed]
- 35. Abou, D.S.; Pickett, J.; Mattson, J.E.; Thorek, D.L.J. A Radium-223 microgenerator from cyclotron-produced trace Actinium-227. *Appl. Radiat. Isot.* **2017**, *119*, 36–42. [CrossRef] [PubMed]
- 36. Müller, C.; Reber, J.; Haller, S.; Dorrer, H.; Köster, U.; Johnston, K.; Zhernosekov, K.; Türler, A.; Schibli, R. Folate receptor targeted alpha-therapy using Terbium-149. *Pharmaceuticals* **2014**, *7*, 353–365. [CrossRef]
- 37. Bosley, R.B.; Simpson, J.A. Choice of alpha-probe operating voltage to suit a wide range of conditions. *J. Radiol. Prot.* **2002**, 22, 293–303. [CrossRef]
- Crompton, A.J.; Gamage, K.A.A.; Jenkins, A.; Taylor, C.J. Alpha particle detection using alpha-induced air radioluminescence: A review and future prospects for preliminary radiological characterisation for nuclear facilities decommissioning. *Sensors* 2018, 18, 1015. [CrossRef]
- Sand, J.; Hannuksela, V.; Ihantola, S.; Perajarvi, K.; Toivonen, H.; Toivonen, J. Remote Optical Detection of Alpha Radiation. IAEA, International Nuclear Information System, 2010 Ref: IAEA-CN-184/23. Available online: http://www.iaea.org/inis/collection/ NCLCollectionStore/_Public/42/081/42081464.pdf (accessed on 14 July 2020).
- Baidoo, K.E.; Milenic, D.E.; Brechbiel, M.W. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl. Med. Biol. 2013, 40, 592–599. [CrossRef]
- 41. Brechbiel, M.W. Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imaging 2007, 52, 166–173.
- 42. Navalkissoor, S.; Grossman, A. Targeted alpha particle therapy for neuroendocrine tumours: The next generation of peptide receptor radionuclide therapy. *Neuroendocrinology* **2019**, *108*, 256–264. [CrossRef]
- 43. Ramogida, C.F.; Robertson, A.K.H.; Jermilova, U.; Zhang, C.; Yang, H.; Kunz, P.; Lassen, J.; Bratanovic, I.; Brown, V.; Southcott, L.; et al. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac. *EJNMMI Radiopharm. Chem.* 2019, *4*, 1–20. [CrossRef] [PubMed]
- Stein, B.W.; Morgenstern, A.; Batista, E.R.; Birnbaum, E.R.; Bone, S.E.; Cary, S.K.; Ferrier, M.G.; John, K.D.; Pacheco, J.L.; Kozimor, S.A.; et al. Advancing chelation chemistry for actinium and other +3 f-Elements, Am, Cm, and La. *J. Am. Chem. Soc.* 2019, 141, 19404–19414. [CrossRef] [PubMed]
- 45. Yang, H.; Zhang, C.; Yuan, Z.; Rodriguez-Rodriguez, C.; Robertson, A.; Radchenko, V.; Perron, R.; Gendron, D.; Causey, P.; Gao, F.; et al. Synthesis and evaluation of a new macrocyclic Actinium-225 chelator, quality control and in vivo evaluation of 225Ac-crown-αMSH peptide. *Chem. A Eur. J.* **2020**, *26*, 11435–11440. [CrossRef] [PubMed]
- Šimeček, J.; Hermann, P.; Seidl, C.; Bruchertseifer, F.; Morgenstern, A.; Wester, H.J.; Notni, J. Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: Towards improved alpha-therapeutics. *EJNMMI Res.* 2018, *8*, 1–6. [CrossRef] [PubMed]
- 47. Hassfjell, S.; Bruland, Ø.S.; Hoff, P. 212Bi-DOTMP: An alpha particle emitting bone-seeking agent for targeted radiotherapy. *Nucl. Med. Biol.* **1997**, *24*, 231–237. [CrossRef]
- 48. Kirby, H.W.; Morss, L.R. Actinium. In *The Chemistry of the Actinide and Transactinide Elements*; Morss, L.R., Edelstein, N.M., Fuger, J., Eds.; Springer: Dordrecht, The Netherlands, 2008. [CrossRef]
- 49. Price, E.W.; Orvig, C. Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 2014, 43, 260–290. [CrossRef]
- Thiele, N.A.; Brown, V.; Kelly, J.M.; Amor-Coarasa, A.; Jermilova, U.; Macmillan, S.N.; Nikolopoulou, A.; Ponnala, S.; Ramogida, C.F.; Robertson, A.K.H.; et al. An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy. *Angew. Chem. Int. Ed.* 2017, 56, 14712–14717. [CrossRef]
- 51. Thiele, N.A.; Wilson, J.J. Actinium-225 for targeted α therapy: Coordination chemistry and current chelation approaches. *Cancer Biother. Radiopharm.* **2018**, *33*, 336–348. [CrossRef]
- 52. Deal, K.A.; Davis, I.A.; Mirzadeh, S.; Kennel, S.J.; Brechbiel, M.W. Improved in vivo stability of actinium-225 macrocyclic complexes. J. Med. Chem. 1999, 42, 2988–2992. [CrossRef]

- 53. Li, L.; Rousseau, J.; Jaraquemada-Peláez, M.D.G.; Wang, X.; Robertson, A.; Radchenko, V.; Schaffer, P.; Lin, K.-S.; Benard, F.; Orvig, C. 225Ac-H4py4pa for targeted alpha therapy. *Bioconjug. Chem.* **2020**. [CrossRef]
- 54. Bartoś, B.; Lyczko, K.; Kasperek, A.; Krajewski, S.; Bilewicz, A. Search of ligands suitable for 212Pb/212Bi in vivo generators. *J. Radioanal. Nucl. Chem.* 2013, 295, 205–209. [CrossRef] [PubMed]
- 55. Ramdahl, T.; Bonge-Hansen, H.T.; Ryan, O.B.; Larsen, Å.; Herstad, G.; Sandberg, M.; Bjerke, R.M.; Grant, D.; Brevik, E.M.; Cuthbertson, A. An efficient chelator for complexation of thorium-227. *Bioorg. Med. Chem. Lett.* 2016, 26, 4318–4321. [CrossRef] [PubMed]
- 56. Zalutsky, M.R.; Bigner, D.D. Radioimmunotherapy with α-particle emitting radioimmunoconjugates. *Acta Oncol.* **1996**, *35*, 373–379. [CrossRef] [PubMed]
- 57. Wilbur, D.S.; Chyan, M.-K.; Nakamae, H.; Chen, Y.; Hamlin, D.K.; Santos, E.B.; Kornblit, B.T.; Sandmaier, B.M. Reagents for Astatination of Biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. *Bioconjugate Chem.* **2012**, *23*, 409–420. [CrossRef]
- Vaidyanathan, G.; Zalutsky, M.R. Astatine Radiopharmaceuticals: Prospects and problems. *Curr. Radiopharm.* 2008, 1, 177–196. [CrossRef] [PubMed]
- 59. Müller, C.; Vermeulen, C.; Köster, U.; Johnston, K.; Türler, A.; Schibli, R.; van der Meulen, N.P. Alpha-PET with terbium-149: Evidence and perspectives for radiotheragnostics. *EJNMMI Radiopharm Chem.* **2017**, *1*, 5. [CrossRef] [PubMed]
- 60. Nedrow, J.R.; Josefsson, A.; Park, S.; Bäck, T.A.; Hobbs, R.F.; Brayton, C.; Bruchertseifer, F.; Morgenstern, A.; Sgouros, G. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. *EJNMMI Res.* **2017**, *7*, 57. [CrossRef]
- 61. Al Darwish, R.; Staudacher, A.H.; Li, Y.; Brown, M.P.; Bezak, E. Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy. *Med. Phys.* **2016**, *43*, 6145–6153. [CrossRef]
- Ackerman, N.L.; Graves, E.E. The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides. *Phys. Med. Biol.* 2012, 57, 771–783. [CrossRef]
- 63. Lloyd, R.D.; Mays, C.W.; Taylor, G.N.; Atherton, D.R.; Bruenger, F.W.; Jones, C.W. Radium-224 retention, distribution, and dosimetry in beagles. *Radiat. Res.* **1982**, *92*, 280. [CrossRef]
- Schwartz, J.; Jaggi, J.S.; O'Donoghue, J.A.; Ruan, S.; McDevitt, M.; Larson, S.M.; Scheinberg, D.A.; Humm, J.L. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. *Phys. Med. Biol.* 2011, 56, 721–733. [CrossRef] [PubMed]
- Baum, R.P.; Langbein, T.; Singh, A.; Shahinfar, M.; Schuchardt, C.; Volk, G.F.; Kulkarni, H. Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: An empirical proof of a promising concept. *Nucl. Med. Mol. Imaging* 2018, 52, 80–81. [CrossRef] [PubMed]
- 66. Carrasquillo, J.A.; O'Donoghue, J.A.; Pandit-Taskar, N.; Humm, J.L.; Rathkopf, D.E.; Slovin, S.F.; Williamson, M.J.; Lacuna, K.; Aksnes, A.-K.; Larson, S.M.; et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* **2013**, 40, 1384–1393. [CrossRef] [PubMed]
- 67. Jonasdottir, T.; Fisher, D.R.; Borrebaek, J.; Bruland, O.S.; Larsen, R. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. *Anticancer. Res.* **2006**, *26*, 2841–2848.
- Sofou, S.; Kappel, B.J.; Jaggi, J.S.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers. *Bioconjugate Chem.* 2007, *18*, 2061–2067. [CrossRef]
- Cędrowska, E.; Pruszynski, M.; Majkowska-Pilip, A.; Męczyńska-Wielgosz, S.; Bruchertseifer, F.; Morgenstern, A.; Bilewicz, A. Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy. J. Nanoparticle Res. 2018, 20, 1–10. [CrossRef]
- 70. McLaughlin, M.F.; Woodward, J.; Boll, R.A.; Wall, J.S.; Rondinone, A.J.; Kennel, S.J.; Mirzadeh, S.; Robertson, J.D. Gold Coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. *PLoS ONE* **2013**, *8*, e54531. [CrossRef]
- 71. Arazi, L.; Cooks, T.; Schmidt, M.; Keisari, Y.; Kelson, I. The treatment of solid tumors by alpha emitters released from224Ra-loaded sources—Internal dosimetry analysis. *Phys. Med. Biol.* **2010**, *55*, 1203–1218. [CrossRef]
- 72. Jaggi, J.S.; Shao, Q.; Wang, H.; McLachlan, E.; Veitch, G.I.; Laird, D.W. Efforts to control the errant products of a targeted in vivo generator. *Cancer Res.* 2005, *65*, 4888–4895. [CrossRef]
- Kraeber-Bodéré, F.; Erousseau, C.; Ebodet-Milin, C.; Eframpas, E.; Efaivre-Chauvet, A.; Erauscher, A.; Sharkey, R.M.; Goldenberg, D.M.; Chatal, J.-F.; Ebarbet, J. A pretargeting system for tumor PET imaging and radioimmunotherapy. *Front. Pharmacol.* 2015, 6, 54. [CrossRef]
- 74. Marcu, L.; Bezak, E.; Allen, B.J. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. *Crit. Rev. Oncol.* 2018, 123, 7–20. [CrossRef] [PubMed]
- 75. Kratochwil, C.; Giesel, F.L.; Bruchertseifer, F.; Mier, W.; Apostolidis, C.; Boll, R.A.; Murphy, K.; Haberkorn, U.; Morgenstern, A. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience. *Eur. J. Nucl. Med. Mol. Imaging* 2014, 41, 2106–2119. [CrossRef] [PubMed]
- 76. Zhang, J.; Kulkarni, H.R.; Baum, R.P. Peptide receptor radionuclide therapy using 225Ac-DOTATOC achieves partial remission in a patient with progressive neuroendocrine liver metastases after repeated β-emitter peptide receptor radionuclide therapy. *Clin. Nucl. Med.* **2020**, 45, 241–243. [CrossRef] [PubMed]

- 77. Ludwig, D.L.; Bryan, R.A.; Dawicki, W.; Geoghegan, E.M.; Liang, Q.; Gokhale, M.; Reddy, V.; Garg, R.; Allen, K.J.; Berger, M.S.; et al. Preclinical development of an Actinium-225-Labeled antibody radio-conjugate directed against CD45 for targeted conditioning and radioimmunotherapy. *Biol. Blood Marrow Transpl.* 2020, 26, S160–S161. [CrossRef]
- Kasten, B.B.; Oliver, P.; Kim, H.; Fan, J.; Ferrone, S.; Zinn, K.R.; Buchsbaum, D.J. 212Pb-labeled antibody 225.28 targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse models. *Int. J. Mol. Sci.* 2018, 19, 925.
 [CrossRef]
- 79. Current, K.; Meyer, C.; Magyar, C.E.; Mona, C.E.; Almajano, J.; Slavik, R.; Stuparu, A.D.; Cheng, C.; Dawson, D.W.; Radu, C.G.; et al. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. *Clin. Cancer Res.* **2020**, *26*, 2946–2955. [CrossRef]
- Hammer, S.; Hagemann, U.B.; Zitzmann-Kolbe, S.; Larsen, A.; Ellingsen, C.; Geraudie, S.; Grant, D.; Indrevoll, B.; Smeets, R.; von Ahsen, O.; et al. Preclinical efficacy of a PSMA-targeted thorium-227 Conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. *Clin. Cancer Res.* 2020, *26*, 1985–1996. [CrossRef]
- 81. Behling, K.; Maguire, W.F.; Puebla, J.C.L.; Sprinkle, S.R.; Ruggiero, A.; O'Donoghue, J.; Gutin, P.H.; Scheinberg, D.A.; McDevitt, M.R. Vascular targeted radioimmunotherapy for the treatment of glioblastoma. *J. Nucl. Med.* **2016**, *57*, 1576–1582. [CrossRef]
- Królicki, L.; Bruchertseifer, F.; Kunikowska, J.; Koziara, H.; Królicki, B.; Jakuciński, M.; Pawlak, D.; Apostolidis, C.; Mirzadeh, S.; Rola, R.; et al. Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 46, 614–622. [CrossRef]
- Zalutsky, M.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical experience with alpha-Particle Emitting 211At: Treatment of recurrent brain tumor patients with 211At-Labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 2007, 49, 30–38. [CrossRef]
- Park, S.I.; Shenoi, J.; Pagel, J.M.; Hamlin, D.K.; Wilbur, D.S.; Orgun, N.; Kenoyer, A.L.; Frayo, S.; Axtman, A.; Bäck, T.A.; et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: A preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. *Blood* 2010, 116, 4231–4239. [CrossRef] [PubMed]
- 85. Dahle, J.; Jonasdottir, T.J.; Heyerdahl, H.; Nesland, J.M.; Borrebaek, J.; Hjelmerud, A.K.; Larsen, R.H. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab. *Eur. J. Nucl. Med. Mol. Imaging* **2009**, *37*, 93–102. [CrossRef] [PubMed]
- Hagemann, U.B.; Wickstroem, K.; Wang, E.; Shea, A.O.; Sponheim, K.; Karlsson, J.; Bjerke, R.M.; Ryan, O.B.; Cuthbertson, A.S. In vitro and in vivo efficacy of a novel CD33-Targeted Thorium-227 conjugate for the treatment of acute myeloid leukemia. *Mol. Cancer Ther.* 2016, 15, 2422–2431. [CrossRef] [PubMed]
- Jurcic, J.G.; Rosenblat, T.L. Targeted alpha-particle immunotherapy for acute myeloid leukemia. *Am. Soc. Clin. Oncol. Educ. Book* 2014, e126–e131. [CrossRef] [PubMed]
- 88. Henriksen, G.; Breistøl, K.; Bruland, Ø.S.; Fodstad, Ø.; Larsen, R. Significant antitumor effect from bone-seeking, alpha-particleemitting (223)Ra demonstrated in an experimental skeletal metastases model. *Cancer Res.* **2002**, *62*, 3120–3125. [PubMed]
- Westrøm, S.; Malenge, M.; Jorstad, I.S.; Napoli, E.; Bruland, Ø.S.; Bønsdorff, T.B.; Larsen, R.H. Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice. *J. Label. Compd. Radiopharm.* 2018, *61*, 472–486. [CrossRef]
- 90. Kasten, B.B.; Gangrade, A.; Kim, H.; Fan, J.; Ferrone, S.; Ferrone, C.R.; Zinn, K.R.; Buchsbaum, D.J. 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. *Nucl. Med. Biol.* **2018**, *58*, 67–73. [CrossRef]
- 91. Zhao, B.; Qin, S.; Chai, L.; Lu, G.; Yang, Y.; Cai, H.; Yuan, X.; Fan, S.; Huang, Q.; Yu, F. Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment. *Bioorganic Med. Chem.* **2018**, *26*, 1086–1091. [CrossRef]
- 92. Li, H.K.; Sugyo, A.; Tsuji, A.B.; Morokoshi, Y.; Minegishi, K.; Nagatsu, K.; Kanda, H.; Harada, Y.; Nagayama, S.; Katagiri, T.; et al. α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. *Cancer Sci.* 2018, 109, 2302–2309. [CrossRef]
- 93. Autenrieth, M.E.; Seidl, C.; Bruchertseifer, F.; Horn, T.; Kurtz, F.; Feuerecker, B.; D'Alessandria, C.; Pfob, C.; Nekolla, S.; Apostolidis, C.; et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: A pilot study. *Eur. J. Nucl. Med. Mol. Imaging* **2018**, *45*, 1364–1371. [CrossRef]
- 94. Popovtzer, A.; Rosenfeld, E.; Mizrachi, A.; Bellia, S.; Ben-Hur, R.; Feliciani, G.; Sarnelli, A.; Arazi, L.; Deutsch, L.; Kelson, I.; et al. Initial safety and tumor control results from a "First-in-Human" multicenter prospective trial evaluating a novel alpha-emitting radionuclide for the treatment of locally advanced recurrent squamous cell carcinomas of the skin and head and neck. *Int. J. Radiat. Oncol.* 2020, 106, 571–578. [CrossRef] [PubMed]
- 95. Pruszyński, M.; D'Huyvetter, M.; Bruchertseifer, F.; Morgenstern, A.; Lahoutte, T. Evaluation of an Anti-HER2 nanobody labeled with 225Ac for targeted α-Particle therapy of cancer. *Mol. Pharm.* **2018**, *15*, 1457–1466. [CrossRef] [PubMed]
- 96. Fichou, N.; Gouard, S.; Maurel, C.; Barbet, J.; Ferrer, L.; Morgenstern, A.; Bruchertseifer, F.; Faivre-Chauvet, A.; Bigot-Corbel, E.; Davodeau, F.; et al. Single-Dose Anti-CD138 radioimmunotherapy: Bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model. *Front. Med.* 2015, *2*, 76. [CrossRef] [PubMed]
- McDevitt, M.R.; Barendswaard, E.; Ma, D.; Lai, L.; Curcio, M.J.; Sgouros, G.; Ballangrud, A.M.; Yang, W.H.; Finn, R.D.; Pellegrini, V.; et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. *Cancer Res.* 2000, 60, 6095–6100. [PubMed]

- Winter, B.M.; Von Rundstedt, F.-C.; Grimm, M.-O. Alpharadin-Therapie bei Patienten mit metastasiertem kastrationsrefraktärem Prostatakarzinom Radium-223 dichloride in patients with castration-refractory prostate cancer. *Der Urol.* 2017, *56*, 1435–1439. [CrossRef]
- Juzeniene, A.; Bernoulli, J.; Suominen, M.; Halleen, J.; Larsen, R.H. Antitumor activity of novel bone-seeking, α-emitting 224Ra-solution in a breast cancer skeletal metastases model. *Anticancer. Res.* 2018, *38*, 1947–1955. [CrossRef]
- 100. Cooks, T.; Tal, M.; Raab, S.; Efrati, M.; Reitkopf, S.; Lazarov, E.; Etzyoni, R.; Schmidt, M.; Arazi, L.; Kelson, I.; et al. Intratumoral 224Ra-loaded wires spread alpha-emitters inside solid human tumors in athymic mice achieving tumor control. *Anticancer. Res.* 2012, 32, 5315–5321.
- Banerjee, S.R.; Minn, I.; Kumar, V.; Josefsson, A.; Lisok, A.; Brummet, M.; Chen, J.; Kiess, A.P.; Baidoo, K.; Brayton, C.; et al. Preclinical evaluation of 203/212Pb-Labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J. Nucl. Med. 2020, 61, 80–88. [CrossRef]
- 102. Boudousq, V.; Bobyk, L.; Busson, M.; Garambois, V.; Jarlier, M.; Charalambatou, P.; Pèlegrin, A.; Paillas, S.; Chouin, N.; Quenet, F.; et al. Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. *PLoS ONE* **2013**, *8*, e69613. [CrossRef]
- Stenberg, V.Y.; Juzeniene, A.; Chen, Q.; Yang, X.; Bruland, Ø.S.; Larsen, R.H. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer. J. Label. Compd. Radiopharm. 2020, 63, 129–143. [CrossRef]
- 104. Choi, J.; Vaidyanathan, G.; Koumarianou, E.; Kang, C.M.; Zalutsky, M. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: Radiolabeling and preliminary evaluation. *Nucl. Med. Biol.* 2017, *56*, 10–20. [CrossRef] [PubMed]
- 105. Dekempeneer, Y.; Bäck, T.; Aneheim, E.; Jensen, H.; Puttemans, J.; Xavier, C.; Keyaerts, M.; Palm, S.; Albertsson, P.; Lahoutte, T.; et al. Labeling of Anti-HER2 Nanobodies WITH Astatine-211: Optimization and the effect of different coupling reagents on their in vivo behavior. *Mol. Pharm.* 2019, *16*, 3524–3533. [CrossRef] [PubMed]
- 106. O'Steen, S.; Comstock, M.L.; Orozco, J.J.; Hamlin, D.K.; Wilbur, D.S.; Jones, J.; Kenoyer, A.; Nartea, M.E.; Lin, Y.; Miller, B.W.; et al. The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. *Blood* 2019, 134, 1247–1256. [CrossRef] [PubMed]
- 107. Li, H.K.; Hasegawa, S.; Nakajima, N.I.; Morokoshi, Y.; Minegishi, K.; Nagatsu, K. Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B. *Biochem. Biophys. Res. Commun.* **2018**, *506*, 1078–1084. [CrossRef]
- 108. Beyer, G.-J.; Miederer, M.; Vranješ-Đurić, S.; Čomor, J.J.; Künzi, G.; Hartley, O.; Senekowitsch-Schmidtke, R.; Soloviev, D.; Buchegger, F. Targeted alpha therapy in vivo: Direct evidence for single cancer cell kill using 149Tb-rituximab. *Eur. J. Nucl. Med. Mol. Imaging* 2004, 31, 547–554. [CrossRef]
- 109. Bräuer, A.; Grubert, L.S.; Roll, W.; Schrader, A.J.; Schäfers, M.; Bögemann, M.; Rahbar, K. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2017, 44, 1663–1670. [CrossRef]
- Kratochwil, C.; Haberkorn, U.; Giesel, F.L. 225Ac-PSMA-617 for Therapy of Prostate Cancer. Semin. Nucl. Med. 2020, 50, 133–140.
 [CrossRef]
- Sathekge, M.; Bruchertseifer, F.; Knoesen, O.; Reyneke, F.; Lawal, I.; Lengana, T.; Davis, C.; Mahapane, J.; Corbett, C.; Vorster, M. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: A pilot study. *Eur. J. Nucl. Med. Mol. Imaging.* 2019, 46, 129–138. [CrossRef]
- 112. Nilsson, S.; Larsen, R.; Fosså, S.D.; Balteskard, L.; Borch, K.W.; Westlin, J.-E.; Salberg, G.; Bruland, Ø.S. First Clinical Experience with alpha-Emitting Radium-223 in the Treatment of Skeletal Metastases. *Clin. Cancer Res.* 2005, *11*, 4451–4459. [CrossRef]
- 113. Sartor, O.; Coleman, R.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O'Sullivan, J.M.; Fosså, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. *Lancet Oncol.* **2014**, *15*, 738–746. [CrossRef]
- 114. Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S.; O'Sullivan, J.; Fosså, S.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N. Engl. J. Med.* **2013**, *369*, 213–223. [CrossRef] [PubMed]
- 115. European Medicines Agency. EMA Restricts Use of Prostate Cancer Medicine Xofigo. Available online: https://www.ema.europa.eu/en/medicines/human/referrals/xofigo (accessed on 11 November 2018).
- 116. Meredith, R.; Torgue, J.; Shen, S.; Fisher, D.R.; Banaga, E.; Bunch, P.; Morgan, D.; Fan, J.; Straughn, J.M., Jr. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. *J. Nucl. Med.* 2014, 55, 1636–1642. [CrossRef] [PubMed]
- 117. Li, Y.; Hamlin, D.K.; Chyan, M.-K.; Wong, R.; Dorman, E.F.; Emery, R.C.; Woodle, D.R.; Manger, R.L.; Nartea, M.; Kenoyer, A.L.; et al. cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. *PLoS ONE* 2018, *13*, e0205135. [CrossRef] [PubMed]
- 118. Andersson, H.; Cederkrantz, E.; Bäck, T.; Divgi, C.; Elgqvist, J.; Himmelman, J.; Horvath, G.; Jacobsson, L.; Jensen, H.; Lindegren, S.; et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of 211At-MX35 F(ab')2—A phase I study. J. Nucl. Med. 2009, 50, 1153–1160. [CrossRef]